Document:

Assignment and Assumption Agreement

 EXHIBIT 10.64 
 ASSIGNMENT AND ASSUMPTION AGREEMENT 
 THIS
ASSIGNMENT AND ASSUMPTION AGREEMENT (this “Agreement”), is made as of the 11th day of January, 2010, by and between JAY LEVY (the “Assignor”) and JEAN LEVY (the “Assignee”). 
 WITNESSETH 
 WHEREAS, the Assignor has certain rights and obligations under that certain promissory note dated September 30, 2008, between UNIGENE LABORATORIES, INC. (the “Company”) as Maker and the Assignor, or his registered assigns, as
Holder, with an initial principal amount of Eight Million, Three Hundred Eighteen Thousand, Seven Hundred Fourteen and 00/100 Dollars ($8,318,714.00) (the “Note”, a copy of which is attached as an Exhibit hereto). 
 WHEREAS, the Assignor desires to transfer the Note and assign to the Assignee One-Hundred Percent (100%) of the Assignor’s rights,
title, interests and obligations under the Note to the Assignee. 
 WHEREAS, the Assignee desires to accept from the Assignor
the Note and One-Hundred Percent (100%) of the Assignor’s rights, title, interests and obligations under the Note. 
 NOW, THEREFORE, for love and affection, and other good and valuable consideration, the parties agree as follows: 
 1.
Assignment. The Assignor hereby assigns, transfers and conveys to the Assignee the Note and One-Hundred Percent (100%) of the Assignor’s rights, title, interests and obligations under the Note. 
 2. Assumption. The Assignee hereby accepts and assumes the Note and One-Hundred Percent (100%) of the Assignor’s rights, title, interests
and obligations under the Note. 
 3. Assurance of Further Action. From time to time after the date hereof and without further
consideration from the Assignee, but at the Assignee’s sole expense, the Assignor shall execute and deliver, or cause to be executed and delivered, to the Assignee such further instruments of sale, assignment, transfer and delivery and take
such other action as the Assignee or the Company (as defined in the Note) may reasonably request in order to consummate the transactions contemplated hereby. 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed the day and year
first above written. 
  

	
	ASSIGNOR:
	
	 /s/ Jay Levy

	JAY LEVY
	
	ASSIGNEE:
	
	 /s/ Jay Levy

	JAY LEVY, as Attorney-In-Fact for
	JEAN LEVY

 CONSENT PURSUANT TO PARAGRAPH 10(B) OF
THE NOTE: 
 The Company, as Maker of the Note, hereby consents to the Assignment of the Note from Assignor to Assignee and acknowledges
that all of the Assignor’s rights, title, interests and obligations under the Note have been assigned by the Assignor to the Assignee, and that the Undersigned shall deliver all future payments under the Note to the Assignee and not the
Assignor, except as may otherwise be required under the Note.. 
 UNIGENE LABORATORIES, INC. 
  

			
	By:	 	 /s/ William Steinhauer

	Name:	 	William Steinhauer
	Title:	 	VP of Finance

  

 2 

 This instrument and the rights, remedies and obligations evidenced hereby are subordinate in the
manner and to the extent set forth in that certain Affiliate Subordination Agreement (as amended, restated, modified or supplemented from time to time, the “Subordination Agreement”) dated as of
September 30, 2008, by and among Jay Levy, Jaynjean Levy Family Limited Partnership, Unigene Laboratories, Inc. and Victory Park Management, LLC, to the Senior Debt (as defined in the Subordination Agreement); and each holder of this
instrument, by its acceptance hereof, irrevocably agrees to be bound by the provisions of the Subordination Agreement. 
 UNIGENE LABORATORIES, INC. 
 AMENDED AND RESTATED 
 SECURED PROMISSORY NOTE 
  

			
	$8,318,714.00	  	September 30, 2008
		  	Fairfield, New Jersey

 FOR VALUE
RECEIVED Unigene Laboratories, Inc., a Delaware corporation (the “Company”), promises to pay to Jay Levy (the “Holder”), or his registered assigns, the principal sum of Eight Million, Three Hundred
Eighteen Thousand, Seven Hundred Fourteen and 00/100 Dollars ($8,318,714.00), or such lesser amount as shall equal the outstanding principal amount hereof, together with interest from May 10, 2007 on the unpaid principal balance at a rate equal
to nine percent (9.00%) per annum, which shall be non-compounding, computed on the basis of the actual number of days elapsed and a year of 365 days. All unpaid principal, together with any then unpaid and accrued interest and other amounts
payable hereunder, shall be due and payable on the earlier of (i) February 10, 2015 (the “Maturity Date”), or (ii) when, upon or after the occurrence of an Event of Default (as defined below), such amounts are
declared due and payable by the Holder or made automatically due and payable in accordance with the terms hereof. This Note is issued pursuant to the Amended and Restated Security Agreement, dated May 10, 2007, entered into by and between the
Company and the Holder (as amended, restated, modified or supplemented from time to time, the “Security Agreement”). The Prior Note (as defined below) replaced in their entirety those notes listed on Exhibit A hereto
and was not intended to be a novation of said notes, but rather evidenced and documented the continuation of all obligations and liabilities outstanding thereunder, including, without limitation, principal, interest, penalties and fees, as more
fully described herein. 
 THE OBLIGATIONS DUE UNDER THIS NOTE ARE SECURED BY THE SECURITY AGREEMENT AND THE THIRD MODIFICATION OF MORTGAGE AND
SECURITY AGREEMENT, ENTERED INTO ON THE DATE HEREOF BY THE COMPANY IN FAVOR OF HOLDER (AS MAY BE AMENDED AND/OR RESTATED FROM TIME TO TIME, THE “THIRD MODIFICATION”). ADDITIONAL RIGHTS OF HOLDER ARE SET FORTH IN THE SECURITY
AGREEMENT AND THE THIRD MODIFICATION. 
 The following is a statement of the rights of the Holder and the conditions to which this Note is
subject, and to which the Holder, by the acceptance of this Note, agrees: 
 1. Amendment and Restatement.
Effective as of the date hereof, this Note amends and restates in its entirety the Secured Promissory Note dated May 10, 2007 (the “Prior Note”) issued by the Company to the Holder in the principal amount of Eight
Million, Three Hundred Eighteen Thousand, Seven Hundred Fourteen and 00/100 Dollars ($8,318,714.00). This Note (a) is made in substitution for, and not as payment of, the obligations of the Company under the Prior Note and (b) is not
intended to constitute a novation or discharge of the Prior Note. On and after the date hereof, all principal of, and accrued but unpaid interest on, the Prior Note (i) shall remain outstanding under this Note and (ii) shall be governed by
the terms of this Note and the Security Agreement. 

 2. Definitions. As used in this Note, the following capitalized terms
have the following meanings: 
 (a) “Affiliate” with respect to any Person, means (i) any director
or officer of such Person, (ii) any Person directly or indirectly controlling or controlled by or under direct or indirect common control with such Person, and (iii) any Person beneficially owning or holding 5% or more of any class of
voting securities of such Person or any corporation of which such Person beneficially owns or holds, in the aggregate, 5% or more of any class of voting securities. The term “control” means the possession, directly or indirectly, of the
power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. 
 (b) “Business Day” means any day other than a Saturday, Sunday or public holiday under the laws of the United States of America or the State of New Jersey or any
other day on which banking institutions are authorized or obligated to close in the State of New Jersey. 
 (c)
“Change in Control” means any of the following: (i) any Person, either individually or acting in concert with one or more other Persons, shall have acquired beneficial ownership, directly or indirectly, of
stock or other securities of the Company (or other securities convertible into stock or other securities) representing 50% or more of the combined voting power of all stock or other securities of the Company entitled to vote in the election of
members of the board of directors of the Company, other than stock or other securities having such power only by reason of the happening of a contingency; or (ii) the occurrence of a change in the composition of the board of directors of the
Company such that a majority of the members thereof are not continuing members. As used herein, (a) the term “beneficially own” or “beneficial ownership” shall have the meaning set forth in the Securities Exchange Act of
1934, as amended from time to time, and the rules and regulations promulgated thereunder and (b) the term “continuing member” shall mean, as of any date of determination, any member of the board of directors of the Company who
(i) was a member of such board on the date of this Note or (ii) was nominated for election or elected to such board with the affirmative vote of a majority of the members who were either members of such board on the date of this Note or
whose nomination or election was previously so approved. 
 (d) “Company” means the
corporation initially executing this Note and any Person which shall succeed to or assume the obligations of the Company under this Note in accordance with the terms hereof 
 (e) “Event of Default” has the meaning given in Section 6 hereof. 
  

 - 2 - 

 (f) “First Quarterly Payment” has the meaning given in
Section 3(a) of this Note. 
 (g) “Holder” means the Person specified
in the first paragraph of this Note or any Person who shall at the time be the registered holder of this Note pursuant to a transfer permitted by the terms of this Note. 
 (h) “Indebtedness” means the aggregate amount of, without duplication (i) all obligations for borrowed money, (ii) all obligations evidenced
by bonds, debentures, notes or other similar instruments, (iii) all obligations to pay the deferred purchase price of property or services (other than accounts payable incurred in the ordinary course of business), (iv) all obligations with
respect to capital leases, (v) all obligations created or arising under any conditional sale or other title retention agreements with respect to property acquired by such Person, (vi) all reimbursement and other payment obligations,
contingent or otherwise, in respect of letters of credit and similar surety instruments, (vii) all payment obligations, contingent or otherwise, pursuant to or arising under currency swap agreements, interest rate swap agreements or other swap
or derivative agreements, and (viii) all guaranty obligations with respect to the types of Indebtedness listed in clauses (i) through (vii) above. 
 (i) “Initial Interest Component” has the meaning set forth in Section 3(b)(ii) of this Note. 
 (j) “Lien” means, with respect to any property, any security interest, mortgage, pledge, lien, claim, charge or other encumbrance in, of, or on such
property or the income therefrom, including, without limitation, the interest of a vendor or lessor under a conditional sale agreement, capital lease or other title retention agreement, or any agreement to provide any of the foregoing, and the
filing of any financing statement or similar instrument under the Uniform Commercial Code or comparable law of any jurisdiction. 
 (k) “Maturity Date” has the meaning set forth in the first paragraph of this Note. 
 (l)
“Obligations” means all loans, advances, debts, liabilities and obligations, howsoever arising, owed by the Company to the Holder of every kind and description (whether or not evidenced by any note
or instrument and whether or not for the payment of money), now existing or hereafter arising under or pursuant to the terms of this Note and the other Transaction Documents, including, all interest, fees, charges, expenses, attorneys’ fees and
costs and accountants’ fees and costs chargeable to and payable by the Company hereunder and thereunder, in each case, whether direct or indirect, absolute or contingent, due or to become due, and whether or not arising after the commencement
of a proceeding under Title 11 of the United States Code (11 U. S. C. Section 101 et seq.), as amended from time to time (including post-petition interest) and whether or not allowed or allowable as a claim in any such proceeding.

  

 - 3 - 

 (m) “Ongoing Interest Component” has the meaning set forth in
Section 3(c)(iii) of this Note. 
 (n) “Permitted Distribution” means:
(i) repurchases of stock from employees, consultants or directors of the Company in an aggregate amount not to exceed $50,000 in any fiscal year; provided that no Event of Default has occurred and is continuing or would exist
after giving effect to the repurchases; (ii) dividends or distributions payable solely in capital stock of the Company; and (iii) any dividend or distribution made by any Subsidiary to another Subsidiary or to the Company. 
 (o) “Permitted Indebtedness” means: (i) Indebtedness of the Company existing on May 10, 2007
as set forth on Schedule A (it being understood that any Indebtedness of the Company existing on May 10, 2007 shall constitute Permitted Indebtedness whether or not listed on Schedule A), and any renewals, refinancings,
replacements and extensions thereof; so long as (A) the principal amount of such Indebtedness does not exceed the principal amount being renewed, refinanced, replaced or extended plus an amount necessary to pay any fees and expenses related
thereto, (B) such Indebtedness does not contain covenants or other restrictions materially more onerous than those contained in the Indebtedness being renewed, refinanced, replaced or extended, and (C) the average life to maturity thereof
is greater than or equal to that of the Indebtedness being renewed, refinanced, replaced or extended; (ii) other unsecured Indebtedness of the Company or any of its Subsidiaries in an aggregate principal amount at any time outstanding not to
exceed $2,000,000; (iii) Indebtedness of the Company or any of its Subsidiaries secured by Liens described in clauses (vi) and (vii) of the definition of Permitted Liens, so long as (A) at the time when such Indebtedness is
incurred, the amount of such Indebtedness does not exceed the fair market value (as reasonably determined by the principal financial officer of the Company in good faith) of the leased property or purchased equipment and (B) the aggregate
amount of such Indebtedness does not exceed $500,000 at any time outstanding; (iv) Indebtedness of any Subsidiary of the Company to the Company or another Subsidiary; (v) Indebtedness pursuant to or arising under currency swap agreements
or interest rate swap agreements or swap or derivative agreements entered into in connection with bona fide hedging arrangements; (vi) Indebtedness of the Company or any of its Subsidiaries subordinated to the Obligations on terms reasonably
satisfactory to the Holder, and having terms and conditions (other than interest and overall yield) more favorable to the Company than the terms and conditions of this Note and the other Transaction Documents (including, without limitation,
covenants and events of default more favorable to the Company than the covenants and events of default hereunder), and having redemption, prepayment and defeasance provisions reasonably satisfactory to the Holder, in an aggregate principal amount
not to exceed $2,000,000 at any time outstanding less any amounts outstanding pursuant to clause (ii) of this definition of Permitted Indebtedness (“Subordinated Indebtedness”); (vii) Senior Debt; and
(viii) the Obligations. 
  

 - 4 - 

 (p) “Permitted Liens” means the following types of
Liens (excluding any such Lien imposed pursuant to Section 401(a)(29) or 412(n) of the Internal Revenue Code, as amended, or by the Employee Retirement Income Security Act of 1974, as amended, or any Lien imposed by a governmental authority
under any applicable environmental law or with respect to a foreign deferred compensation plan): (i) Liens for taxes or other governmental charges not at the time delinquent or thereafter payable without penalty or being contested in good
faith, provided provision is made to the reasonable satisfaction of the Holder for the eventual payment thereof if subsequently found payable; (ii) Liens of carriers, warehousemen, mechanics, materialmen, vendors, and landlords incurred
in the ordinary course of business for sums not overdue or being contested in good faith, provided provision is made to the reasonable satisfaction of the Holder for the eventual payment thereof if subsequently found payable;
(iii) deposits under workers’ compensation, unemployment insurance and social security laws or to secure the performance of bids, tenders, contracts (other than for the repayment of borrowed money) or leases, or to secure statutory
obligations of surety or appeal bonds or to secure indemnity, performance or other similar bonds in the ordinary course of business; (iv) easements, reservations, rights of way, restrictions, minor defects or irregularities in title and other
similar charges or encumbrances affecting real property in a manner not materially or adversely affecting the value or use of such property; (v) Liens in favor of the Holder; (vi) Liens securing obligations under a capital lease so long as
such Liens do not extend to property other than the property leased under such capital lease, and any additions, attachments, improvements and accessions thereto and replacements, substitutions and proceeds (including insurance proceeds) thereof;
(vii) Liens upon any equipment acquired or held by the Company or any of its Subsidiaries to secure the purchase price of such equipment or indebtedness incurred solely for the purpose of financing the acquisition of such equipment, so long as
such Lien extends only to the equipment financed, and any additions, attachments, improvements and accessions thereto and replacements, substitutions and proceeds (including insurance proceeds) thereof; (viii) Liens in favor of customs and
revenue authorities arising as a matter of law to secure payments of customs duties in connection with the importation of goods; (ix) Liens which constitute rights of setoff of a customary nature or banker’s liens, whether arising by
statute, common law or by contract; (x) Liens on insurance proceeds in favor of insurance companies granted solely as security for financed premiums; (xi) Liens arising from judgments, decrees or attachments in circumstances not
constituting an Event of Default under Section 6(g); (xii) Liens existing on May 10, 2007 as set forth on Schedule B (it being understood that any Lien of the Company existing on May 10, 2007 shall constitute a Permitted
Lien whether or not listed on Schedule B) and any renewals, refinancings or extensions thereof that do not increase the amount of Indebtedness secured thereby or encumber additional collateral or contain covenants or other restrictions
materially more onerous than those contained in the Lien being renewed, refinanced or extended; (xiii) leases or subleases and licenses or sublicenses granted in the ordinary course of the Company’s or any Subsidiary’s business;
(xiv) purported Liens evidenced by the filing of precautionary UCC financing statements relating solely to operating leases of personal property; and (xv) Liens incurred pursuant to the Senior Debt Documents. 
 (q) “Person” means an individual, a partnership, a corporation (including a business trust), a joint
stock company, a limited liability company, an unincorporated association, a joint venture or other entity or a governmental authority. 
 (r) “Principal Component” has the meaning set forth in Section 3(b)(i) of this Note. 
  

 - 5 - 

 (s) “Prior Note” has the meaning set forth in Section 1 of this
Note. 
 (t) “Quarterly Payment” has the meaning set forth in Section 3(a) of this Note.

 (u) “Revised Payment Schedule” has the meaning set forth in Section 4(c) of this Note.

 (v) “Security Agreement” has the meaning set forth in the first paragraph of this Note.

 (w) “Senior Debt” has the meaning assigned to such term in the Subordination Agreement (and any
defined terms therein shall have the meanings ascribed to such terms in the Subordination Agreement), and any refinancing thereof under the VPC Loan Documents (as defined in the Subordination Agreement). 
 (x) “Senior Debt Documents” has the meaning assigned to such term in the Subordination Agreement (and
any defined terms therein shall have the meanings ascribed to such terms in the Subordination Agreement). 
 (y)
“Subordination Agreement” means that certain Affiliate Subordination Agreement, dated as of the date hereof, by and among the Company, the Holder, Jaynjean Levy Family Limited Partnership and
Victory Park Management, LLC as Agent, as may be amended, restated, modified or supplemented from time to time. 
 (z)
“Subsidiary” means any other entity included in the financial statements of the Company on a consolidated basis. 
 (aa) “Third Modification” has the meaning set forth in the second paragraph of this Note. 
 (bb) “Transaction Documents” means this Note, the Security Agreement, the New Mortgage Modification
(as defined in the Security Agreement), the Third Modification and each mortgage, pledge agreement, control agreement, grant of security interest in copyrights, patents or trademarks or other instrument or document delivered by the Company pursuant
to the Security Agreement or any of the other Transaction Documents in order to grant the Holder a Lien on any property of the Company as security for the Obligations. 
 (cc) “Transfer” has the meaning set forth in Section 5 of this Note. 
 3. Principal and Interest. 
 (a) The principal of
this Note and interest hereunder shall be due and payable in consecutive quarterly installments beginning on May 10, 2010 (the “First Quarterly Payment”) and on each August 10th, November 10th, February 10th and May 10th of each year thereafter to and including the Maturity Date (each such payment, a “Quarterly
Payment”). 
  

 - 6 - 

 (b) The First Quarterly Payment shall consist of: 
 (i) $415,935.70, representing one-twentieth (1/20th) of the principal, which shall be subject to adjustment pursuant to Section 4(b) herein, as set forth in the
Revised Payment Schedule (as so adjusted, the “Principal Component”); and 
 (ii)
$112,302.64, representing one-twentieth (1/20th) of
the interest that shall have accrued on the unpaid and outstanding principal from the date of this Note through and until the First Quarterly Payment, which shall be subject to adjustment pursuant to Section 4(b) herein, as set forth in the
Revised Payment Schedule (as so adjusted, the “Initial Interest Component”). 
 (c) Each Quarterly
Payment after the First Quarterly Payment shall consist of: 
 (i) the Principal Component; 
 (ii) the Initial Interest Component; and 
 (iii) the product of (1) the then outstanding principal on this Note and (2) the product of (A) nine percent (9.00%) multiplied by (B) a fraction, the numerator of which shall be
the actual number of days elapsed since the most recent Quarterly Payment and the denominator of which shall be 365, which shall represent the interest accruing from Quarterly Payment to Quarterly Payment on this Note (the “Ongoing
Interest Component”). 
 4. Optional Prepayment. 
 (a) Upon five (5) days prior written notice to the Holder, the Company may prepay this Note in whole or in part; provided that
unless otherwise directed by the Holder any such prepayment will be applied (i) first to the payment of expenses due under this Note, (ii) second to the aggregate Initial Interest Component accrued but unpaid up to the date of prepayment,
(iii) third to the Ongoing Interest Component accrued but unpaid up to the date of prepayment and (iv) fourth, if the amount of prepayment exceeds the amount of all such expenses and accrued but unpaid interest, to the payment of then
outstanding principal of this Note, with a prepayment deemed to be applied to the principal component of the last Quarterly Payment then due and owing on this Note. 
 (b) Furthermore, concurrently with any prepayment made pursuant to Section 4(a) of this Note, the Company will
recalculate the Initial Interest Component, the Principal Component and the Ongoing Interest Component if and as necessary to keep the remaining payment schedule consistent with the original payment structure of this Note (i.e., interest shall
accrue on the outstanding principal for the first three (3) years; then, beginning with the third anniversary of this Note and every quarter thereafter, one-twentieth (1/20th) (or such larger fraction if Quarterly Payments have been eliminated in accordance with Section 4(a)(iv) of
this Note) of such principal plus such interest which has accrued during such first three (3) years, together with ongoing interest calculated from Quarterly Payment to Quarterly Payment, shall be paid to the Holder). 
  

 - 7 - 

 (c) Upon such recalculation, the Company shall promptly send the Holder a written schedule
(the “Revised Payment Schedule”) detailing the remaining Quarterly Payments, including the amounts which represent (i) the Principal Component, (ii) the Initial Interest Component and (iii) the Ongoing Interest
Component, and thereafter the Company shall make Quarterly Payments on this Note in accordance with such Revised Payment Schedule. 
 5. Certain Covenants. While any amount is outstanding under the Note, without the prior written consent of the Holder: 
 (a) Indebtedness. Neither the Company nor any of its Subsidiaries shall create, incur, assume or permit to exist any Indebtedness except Permitted Indebtedness. 
 (b) Liens. Neither the Company nor any of its Subsidiaries shall create, incur, assume or permit to exist any Lien on or with respect
to any of its assets or property of any character, whether now owned or hereafter acquired, except for Permitted Liens. 
 (c)
Asset Dispositions. Neither the Company nor any of its Subsidiaries shall sell, lease, transfer, license or otherwise dispose of (collectively, a “Transfer”) any of its assets or property, whether now owned or
hereafter acquired, except (i) Transfers in the ordinary course of its business consisting of (A) the sale of inventory, (B) sales or transfers of surplus, worn-out or obsolete equipment, (C) leases or subleases entered into in
the ordinary course of business or approved by the Holder in writing and (D) licenses of intellectual property or know-how; (ii) a Transfer from any Subsidiary of the Company to the Company or another Subsidiary; (iii) the granting of
Permitted Liens, (iv) expenditures of cash not prohibited by this Note; and (v) Transfers permitted by Section 5(d) or 5(e) of this Note. 
 (d) Mergers, Acquisitions, Etc. Neither the Company nor any of its Subsidiaries may consolidate with or merge into any other Person or permit any other Person to merge into it, or acquire all or
substantially all of the assets or capital stock of any other Person; provided that if the surviving entity of such merger expressly agrees to assume all of the Obligations and covenants of the Company and its Subsidiaries arising
under or pursuant to the terms of this Note and the other Transaction Documents, then such written consent of the Holder shall not be unreasonably withheld. 
 (e) Dividends, Redemptions, Etc. Neither the Company nor any of its Subsidiaries shall (i) pay any dividends or make any distributions on its equity securities; (ii) purchase, redeem,
retire, defease or otherwise acquire for value any of its equity securities; (iii) return any capital to any holder of its equity securities; (iv) make any distribution of assets, equity securities, obligations or securities to any holder
of its equity securities in its capacity as such; or (v) set apart any sum for any such purpose; provided, however, that the Company and its Subsidiaries may make Permitted Distributions. 
  

 - 8 - 

 (f) Indebtedness Payments. Neither the Company nor any of its Subsidiaries shall
(i) prepay, redeem, purchase, defease or otherwise satisfy in any manner prior to the scheduled repayment thereof any Indebtedness (other than amounts due under this Note or the Partnership Note (as defined in the Security Agreement)) or lease
obligations; provided that the Company and its Subsidiaries may prepay, redeem, purchase, defease or otherwise satisfy lease obligations prior to the scheduled repayment thereof in an aggregate amount not to exceed $1,000,000 in any
fiscal year; (ii) amend, modify or otherwise change the terms of any Indebtedness (other than the Obligations) or lease obligations so as to accelerate the scheduled repayment thereof, or (iii) repay any notes to officers, directors or
shareholders (other than the Holder or the holder of the Partnership Note (as defined in the Security Agreement)). Notwithstanding the foregoing sentence, the Company shall not be restricted from (x) paying, defeasing or otherwise satisfying in
any manner the Senior Debt or (y) amending, modifying or otherwise changing the terms of the Senior Debt and the Senior Debt Documents (to the extent and as permitted under the Subordination Agreement). 
 (g) Affiliate Transactions. Neither the Company nor any of its Subsidiaries shall enter into any contractual obligation with any
Affiliate or engage in any other transaction with any Affiliate except (i) upon terms at least as favorable to the Company or such Subsidiary as an arms-length transaction with unaffiliated Persons; provided that the foregoing
shall not apply to transactions involving the Company and its Subsidiaries, (ii) compensation and benefit arrangements (including the granting of options or other equity compensation arrangements) approved by or pursuant to any plan approved by
the board of directors of the Company or a committee thereof, any indemnification arrangements with employees, officers, directors and consultants, and advances to employees of such Person for moving and travel expenses, drawing accounts and similar
expenditures in the ordinary course of business, (iii) any Permitted Indebtedness, (iv) any Permitted Distribution and (v) any transaction with Victory Park Management, LLC and its Affiliates contemplated by the Senior Debt Documents.

 (h) Notice of Defaults. Promptly upon the occurrence thereof, the Company shall furnish to the Holder written notice
of the occurrence of any Event of Default hereunder. Notwithstanding the foregoing, the Company will not be required to disclose, permit the inspection, examination or making of extracts, or discussion of, any document, information or other matter
that (i) constitutes non-financial trade secrets or non-financial proprietary information, (ii) in respect of which disclosure to Holder (or its designated representative) is then prohibited by law, including, without limitation,
Regulation FD promulgated under the Securities Act of 1933, as amended, or any agreement binding on the Company or any of its Subsidiaries or (iii) is subject to attorney-client or similar privilege or constitutes attorney work product.

 (i) Organizational Documents. The Company shall not amend its certificate of incorporation or its bylaws if such
amendment would impair in any material respect the Liens in favor of the Holder granted by the Company pursuant to the Transaction Documents or perfection thereof or the ability of Holder to enforce its rights as set forth in the Transaction
Documents. 
  

 - 9 - 

 (j) Subordinated Indebtedness. Neither the Company nor any of its Subsidiaries shall
amend or otherwise change the terms of any Subordinated Indebtedness, or make any payment consistent with an amendment thereof or change thereto, if the effect of such amendment or change is to increase the interest rate on such Subordinated
Indebtedness, change (to earlier dates) any dates upon which payments of principal or interest are due thereon, change any event of default or condition to an event of default with respect thereto (other than to eliminate any such event of default
or increase any grace period related thereto), change the redemption, prepayment or defeasance provisions thereof, change the subordination provisions thereof (or of any guaranty thereof), or change any collateral therefor (other than to release
such collateral), or if the effect of such amendment or change, together with all other amendments or changes made, is to increase materially the obligations of the obligor thereunder or to confer any additional rights on the holders of such
Subordinated Indebtedness (or a trustee or other representative on their behalf) which would be materially adverse to the Company and its Subsidiaries or the Holder. 
 (k) Inspection Rights. The Holder and its representatives shall have the right, at any time during normal business hours, upon reasonable prior notice which in no case shall be less than five
(5) Business Days unless an Event of Default exists in which case no prior notice is required, to visit and inspect the properties of Company (or any of its Subsidiaries) and its corporate, financial and operating records, and make abstracts
therefrom, and to discuss Company’s affairs, finances and accounts with its directors, officers and independent public accountants; provided that the Holder and any of its representatives who exercise their rights under this
Section 5(k) shall at all times keep confidential and not divulge, furnish or make accessible to anyone any confidential information, knowledge or data concerning or relating to the business or financial affairs of the Company (or any of its
Subsidiaries) to which such party has become privy by reason of this Section 5(k). Notwithstanding the foregoing, the Company will not be required to disclose, permit the inspection, examination or making of extracts, or discussion of, any
document, information or other matter that (i) constitutes non-financial trade secrets or non-financial proprietary information, (ii) in respect of which disclosure to Holder (or its designated representative) is then prohibited by law,
including, without limitation, Regulation FD promulgated under the Securities Act of 1933, as amended, or any agreement binding on the Company or any of its Subsidiaries or (iii) is subject to attorney-client or similar privilege or constitutes
attorney work product. 
 6. Events of Default. The occurrence of any of the following shall constitute an
“Event of Default” under this Note and the other Transaction Documents: 
 (a) Failure to Pay.
The Company shall fail to pay two consecutive Quarterly Payments under this Note on the dates due and such payments shall not have been made in full within thirty (30) days of the Company’s receipt of the Holder’s written notice
(given by any method permitted under Section 12) to the Company of such failure to pay; or 
  

 - 10 - 

 (b) Breaches of Certain Covenants. The Company or any of its Subsidiaries shall fail
to observe or perform any covenant, obligation, condition or agreement set forth in Section 5 of this Note or the other Transaction Documents (other than those specified in Section 6(a)) and (i) such failure shall continue for thirty
(30) days, or (ii) if such failure is not curable within such thirty (30) day period, but is reasonably capable of cure within forty-five (45) days, either (A) such failure shall continue for forty-five (45) days or
(B) the Company or such Subsidiary shall not have commenced a cure in a manner reasonably satisfactory to the Holder within the initial thirty (30) day period; or 
 (c) Representations and Warranties. Any representation, warranty, certificate, or other statement (financial or otherwise) made or
furnished by or on behalf of the Company to Holder in writing in connection with this Note or any of the other Transaction Documents, or as an inducement to the Holder to enter into this Note and the other Transaction Documents, shall be false,
incorrect, incomplete or misleading in any material respect when made or furnished; or 
 (d) Other Payment Obligations.
The Company or any of its Subsidiaries shall (i) fail to make any payment when due under the terms of the Senior Debt Documents and such failure shall continue beyond any period of grace provided with respect thereto, or (ii) default in
the observance or performance of any other agreement, term or condition contained in any such bond, debenture, note or other evidence of Indebtedness, and the effect of such failure or default is to cause the Senior Debt to become due prior to its
stated date of maturity; or 
 (e) Voluntary Bankruptcy or Insolvency Proceedings. The Company or any of its Subsidiaries
shall (i) apply for or consent to the appointment of a receiver, trustee, liquidator or custodian of itself or of all or a substantial part of its property, (ii) be unable, or admit in writing its inability, to pay its debts generally as
they mature, (iii) make a general assignment for the benefit of any of its creditors, (iv) be dissolved or liquidated, (v) become insolvent (as such term may be defined or interpreted under any applicable statute), (vi) commence
a voluntary case or other proceeding seeking liquidation, reorganization or other relief with respect to itself or its debts under any bankruptcy, insolvency or other similar law now or hereafter in effect or consent to any such relief or to the
appointment of or taking possession of its property by any official in an involuntary case or other proceeding commenced against it, or (vii) take any action for the purpose of effecting any of the foregoing; or 
 (f) Involuntary Bankruptcy or Insolvency Proceedings. Proceedings for the appointment of a receiver, trustee, liquidator or custodian
of the Company or any of its Subsidiaries or of all or a substantial part of the property thereof, or an involuntary case or other proceedings seeking liquidation, reorganization or other relief with respect to the Company or any of its Subsidiaries
or the debts thereof under any bankruptcy, insolvency or other similar law now or hereafter in effect shall be commenced and an order for relief entered or such proceeding shall not be dismissed or discharged within sixty (60) days of
commencement; or 
  

 - 11 - 

 (g) Judgments. A final judgment or order for the payment of money in excess of
$2,000,000 (exclusive of amounts covered by insurance issued by an insurer not an Affiliate of Company, to the extent such insurer has acknowledged in writing is obligation to pay such amount) shall be rendered against the Company or any of its
Subsidiaries and the same shall remain undischarged for a period of thirty (30) days during which execution shall not be effectively stayed, or any judgment, writ, assessment, warrant of attachment, or execution or similar process shall be
issued or levied against a substantial part of the property of the Company or any of its Subsidiaries and such judgment, writ, or similar process shall not be released, stayed, vacated or otherwise dismissed within thirty (30) days after issue
or levy; or 
 (h) Transaction Documents. Any Transaction Document or any material term of any thereof shall cease to be,
or be asserted by the Company not to be, a legal, valid and binding obligation of the Company enforceable in accordance with its terms or if the Liens of Holder in any of the assets of Company shall cease to be or shall not be valid, first priority
perfected Liens (subject to Permitted Liens, including, without limitation, Liens incurred in connection with the Senior Debt) or the Company shall assert that such Liens are not valid, first priority and perfected Liens (subject to Permitted Liens,
including, without limitation, Liens incurred in connection with the Senior Debt); or 
 (i) Change in Control. A Change
in Control shall occur. 
 7. Rights of Holder upon Default. Upon the occurrence or existence of any Event of
Default (other than an Event of Default referred to in Section 6(e) or 6(f)) and at any time thereafter during the continuance of such Event of Default, the Holder may, by written notice to the Company, declare all outstanding Obligations to be
immediately due and payable without presentment, demand, protest or any other notice of any kind, all of which are hereby expressly waived, anything contained herein or in the other Transaction Documents to the contrary notwithstanding. Upon the
occurrence or existence of any Event of Default described in Section 6(e) or 6(f), immediately and without notice, all outstanding Obligations shall automatically become immediately due and payable, without presentment, demand, protest or any
other notice of any kind, all of which are hereby expressly waived, anything contained herein or in the other Transaction Documents to the contrary notwithstanding. In addition to the foregoing remedies, upon the occurrence or existence of any Event
of Default, the Holder may exercise any other right, power or remedy granted to it by any of the Transaction Documents or otherwise permitted to it by law, either by suit in equity or by action at law, or both. 
 8. Successors and Assigns. Subject to the restrictions on transfer described in Sections 10 and 11 below, the rights and
obligations of the Company and the Holder of this Note shall be binding upon and benefit the successors, assigns, heirs, administrators and transferees of the parties. 
 9. Waiver and Amendment. Any provision of this Note may be amended, waived or modified only upon the written consent of the Company and the Holder. 
  

 - 12 - 

 10. Transfer of this Note. 
 (a) Transfers of this Note shall be registered upon registration books maintained for such purpose by or on behalf of the Company. Prior to
presentation of this Note for registration of transfer, the Company shall treat the registered holder hereof as the owner and holder of this Note for the purpose of receiving all payments of principal and interest hereon and for all other purposes
whatsoever, whether or not this Note shall be overdue, and the Company shall not be affected by notice to the contrary. Upon such registration, the transferee shall become the “Holder,” “Lender,” “Secured Party” or
“Mortgagee,” as applicable, for all purposes pursuant to the Transaction Documents. 
 (b) Unless an Event of Default
has occurred and is continuing, the Holder may not transfer this Note to any Person without the prior written consent of the Company. 
 11. Assignment by Company. Neither this Note nor any of the rights, interests or obligations hereunder may be assigned, by operation of law or otherwise, in whole or in part, by the Company without the prior written consent of
the Holder (subject to Section 5(d) of this Note). 
 12. Notices. Any notice, request or other communication
required or permitted hereunder shall be in writing and shall be deemed to have been duly given if personally delivered or mailed by registered or certified mail, postage prepaid, or by recognized overnight courier or personal delivery or sent via
facsimile (receipt confirmed) at the respective addresses or facsimile numbers of the parties as set forth in the Security Agreement or on the register maintained by the Company. Any party hereto may by notice so given change its address for future
notice hereunder. Notice shall conclusively be deemed to have been given when received. 
 13. Payment. Payment
shall be made in lawful tender of the United States. 
 14. Usury. In the event any interest is paid on this Note
which is deemed to be in excess of the then legal maximum rate, then that portion of the interest payment representing an amount in excess of the then legal maximum rate shall be deemed a payment of principal and applied against the principal of
this Note. 
 15. Expenses; Waivers. If action is instituted to collect this Note, the Company promises to pay all
costs and expenses, including, without limitation, reasonable attorneys’ fees and costs, incurred in connection with such action. The Company hereby waives notice of default, presentment or demand for payment, protest or notice of nonpayment or
dishonor and all other notices or demands relative to this instrument. 
 16. Governing Law. This Note and all
actions arising out of or in connection with this Note shall be governed by and construed in accordance with the laws of the State of New Jersey, without regard to the conflicts of law provisions of the State of New Jersey, or of any other state.

 [The remainder of this page is intentionally left blank] 
  

 - 13 - 

 IN WITNESS WHEREOF, the parties hereto have executed this Note as of the date first written above.

  

			
	UNIGENE LABORATORIES, INC.,
	a Delaware corporation
		
	By:	 	 /s/ William Steinhauer

	Name:	 	William Steinhauer
	Title:	 	Vice President of Finance

  

	
	 ACKNOWLEDGED AND AGREED

	 TO BY:

	
	 /s/Jay Levy

	JAY LEVY

 [Signature
Page to Note] 

 EXHIIBIT A 
 Outstanding Promissory Notes After Repayment 
 to be
Consolidated into this Note1 
  

													
	  	  	 Date
	  	 Currently
Outstanding
Principal Amount2
	  	 	  	 Date
	  	 Currently
Outstanding
Principal Amount2

	 1
	  	03/02/95	  	$	0	  	1B	  	07/13/99	  	$	1,525,000
	 2
	  	06/29/95	  	 	0	  	2B	  	07/30/99	  	 	70,000
	 3
	  	11/22/99	  	 	0	  	3B	  	08/05/99	  	 	200,000
	 4
	  	02/11/00	  	 	0	  		  	Total:	  	 	1,795,000
	 5
	  	11/13/00	  	 	0	  		  		  		
	 6
	  	11/16/00	  	 	0	  		  		  		
	 7
	  	01/09/01	  	 	0	  	1C	  	02/10/95	  	$	0
	 8
	  	01/16/01	  	 	0	  	2C	  	07/12/00	  	 	0
	 9
	  	02/05/01	  	 	0	  	3C	  	07/31/00	  	 	0
	 10
	  	02/13/01	  	 	0	  	4C	  	08/11/00	  	 	0
	 11
	  	02/22/01	  	 	0	  	5C	  	08/30/00	  	 	0
		  	Total:	  	 	0	  	6C	  	09/13/00	  	 	0
		  		  			  	7C	  	09/27/00	  	 	0
		  		  			  		  	Total:	  	 	0

  

	1	 Not listed here, but also outstanding and included in the amounts that have been consolidated into this Note is a 5% penalty on overdue amounts on
certain notes that were originally payable to Jean Levy, plus accrued interest, which began accruing on 01/01/01. 

	2	 Even though
certain notes listed above have no outstanding principal amount currently due and owing they are listed because interest accrued and continues to be payable thereunder and such interest amounts are being consolidated into this Note.

 SCHEDULE A 
 Permitted Indebtedness 
 The Partnership Note (as defined in the Security Agreement)

 SCHEDULE B 
 Permitted Liens 
 The Patent Security Amendment (as defined in the Security Agreement)

 UCC-1 Financing Statement filed in New Jersey on 6/26/01 in favor of GE Capital Colonial Pacific Leasing (assignee of lessor Genesis
Commercial Capital, LLC) regarding: Equipment/Lease No. 01328-01 
 UCC-1 Financing Statement filed in Delaware on 8/31/01 in favor of GE
Capital Colonial Pacific Leasing regarding: (1) HELOS/BF Particle Size Analyzer; (1) HP Vectra P3/933, 128 Mbyte RAM, 20 GB HD, 48x CD-ROM, NIC, WIN 2000 Operating System; (1) WINDOX Soft on CD-ROM, CRYPTOBOX, Plus Manuals;
(1) IQ/OQ Validation of HELOS; (1) QT Trend Analysis Software Equipment/Lease No: (as continued on 8/29/06) 
 UCC-1 Financing
Statement filed in Delaware on 1/13/03 in favor of CIT Technology Financing Services, Inc. regarding the true lease of “Canon IR5000, sn: MPL17987” plus all other types of office equipment now and hereafter leased to and/or financed for
Debtor/Lessee by Secured Party/Lessor, and including all replacements, upgrades and substitutions hereafter occurring to all the foregoing equipment and all now existing and future attachments, parts, accessories and add-ons for all of the foregoing
items and types of equipment, and all proceeds and products thereof 
 UCC-1 Financing Statement filed in Delaware on 10/8/04 in favor of US
Bancorp regarding: 1 – (S) Akia Purifier 100 with control and accessories 
 UCC-1 Financing Statement filed in New Jersey on 12/16/04
in favor of US Bancorp regarding 1 HPLC system 
 Lien of The Microcap Fund, Inc., a Maryland corporation, on certain patents of the Company

 Lien of Olympus Securities, Ltd., Nelson Partners, Citadel Investment Management, L.P. and Citadel Investment Management, Inc. on certain
patents of the Company 

 EXHIBITLicense Agreement

 EXHIBIT 10.67 
 Portions of this Exhibit were omitted and filed separately with the Secretary of the Commission pursuant to an application for confidential treatment filed with the Commission pursuant to Rule 24b-2
under the Securities Exchange Act of 1934. Such omissions are designated as ***. 
 LICENSE AGREEMENT 
 by and between 
 UNIGENE LABORATORIES, INC. 
 and 
 TARSA THERAPEUTICS, INC. 

 TABLE OF CONTENTS 
  

					
	 	  	 	  	Page
	ARTICLE I DEFINITIONS	  	2
			
	 Section 1.1.
	  	Certain Defined Terms	  	2
			
	 Section 1.2.
	  	Rules of Construction and Interpretation	  	13
		
	ARTICLE II GRANT OF RIGHTS	  	13
			
	 Section 2.1.
	  	License to Tarsa	  	13
			
	 Section 2.2.
	  	License to Unigene	  	15
			
	 Section 2.3.
	  	Manufacturing of Calcitonin API	  	15
			
	 Section 2.4.
	  	Licensed *** Product	  	17
			
	 Section 2.5.
	  	Right to Sublicense	  	18
			
	 Section 2.6.
	  	Marking	  	19
			
	 Section 2.7.
	  	R&D Services	  	19
			
	 Section 2.8.
	  	Additional Services	  	20
			
	 Section 2.9.
	  	Non-Solicitation	  	20
			
	 Section 2.10.
	  	Useful Improvements	  	20
		
	ARTICLE III DEVELOPMENT AND COMMERCIALIZATION OF LICENSED PRODUCTS	  	21
			
	 Section 3.1.
	  	Commercialization	  	21
			
	 Section 3.2.
	  	Product Safety	  	24
			
	 Section 3.3.
	  	Coordination of Development Activities	  	25
			
	 Section 3.4.
	  	Limits on Competing Products	  	25
		
	ARTICLE IV PAYMENTS AND ROYALTIES	  	25
			
	 Section 4.1.
	  	Reimbursement for Phase III Trials	  	25
			
	 Section 4.2.
	  	Royalties	  	26
			
	 Section 4.3.
	  	Milestone Payments	  	28
			
	 Section 4.4.
	  	Payment	  	28
			
	 Section 4.5.
	  	Sales Reports and Royalty Payments	  	28
			
	 Section 4.6.
	  	Tax Withholding; Restrictions on Payment	  	29
			
	 Section 4.7.
	  	Sales Record Audit	  	29

					
	ARTICLE V CONFIDENTIAL INFORMATION	  	29
			
	 Section 5.1.
	  	Confidentiality Obligations	  	29
			
	 Section 5.2.
	  	Exclusions	  	30
			
	 Section 5.3.
	  	Limited Disclosure and Use	  	30
			
	 Section 5.4.
	  	Publicity	  	31
			
	 Section 5.5.
	  	Use of Name; Press Release	  	31
		
	ARTICLE VI INTELLECTUAL PROPERTY	  	31
			
	 Section 6.1.
	  	Licensed IP	  	31
			
	 Section 6.2.
	  	Improvements	  	31
			
	 Section 6.3.
	  	Inventorship	  	32
		
	ARTICLE VII PROVISIONS CONCERNING THE FILING, PROSECUTION AND MAINTENANCE OF LICENSED PATENT RIGHTS	  	32
			
	 Section 7.1.
	  	Cooperation	  	32
			
	 Section 7.2.
	  	Patent Filing, Prosecution and Maintenance	  	32
			
	 Section 7.3.
	  	Notice of Infringement	  	34
			
	 Section 7.4.
	  	Infringement of Unigene-Controlled Patent Rights, Improvements and Unigene Patent Rights	  	34
		
	ARTICLE VIII REPRESENTATIONS, WARRANTIES AND COVENANTS	  	36
			
	 Section 8.1.
	  	Unigene	  	36
			
	 Section 8.2.
	  	Tarsa	  	39
			
	 Section 8.3.
	  	No Warranties	  	39
			
	 Section 8.4.
	  	Indemnification	  	39
			
	 Section 8.5.
	  	LIMITATION OF LIABILITY	  	40
			
	 Section 8.6.
	  	Insurance	  	41
		
	ARTICLE IX TERM AND TERMINATION	  	41
			
	 Section 9.1.
	  	Term	  	41
			
	 Section 9.2.
	  	Termination by Unigene	  	41
			
	 Section 9.3.
	  	Termination by Tarsa	  	43
			
	 Section 9.4.
	  	Effect of Termination by Unigene for Material Breach of Tarsa, by Tarsa Without Cause or for Insolvency	  	43
			
	 Section 9.5.
	  	Tarsa’s Remedies for Material Breach by Unigene	  	44
			
	 Section 9.6.
	  	Remedies	  	45

  

 - ii - 

					
	 Section 9.7.
	  	Surviving Provisions	  	45
			
	 Section 9.8.
	  	Bankruptcy Rights	  	45
		
	ARTICLE X MISCELLANEOUS	  	45
			
	 Section 10.1.
	  	Notification	  	45
			
	 Section 10.2.
	  	Language	  	46
			
	 Section 10.3.
	  	Governing Law; Jurisdiction	  	46
			
	 Section 10.4.
	  	Entire Agreement	  	47
			
	 Section 10.5.
	  	Waiver	  	47
			
	 Section 10.6.
	  	Headings	  	47
			
	 Section 10.7.
	  	Assignment	  	47
			
	 Section 10.8.
	  	Force Majeure	  	47
			
	 Section 10.9.
	  	Construction	  	47
			
	 Section 10.10.
	  	Severability	  	48
			
	 Section 10.11.
	  	Status	  	48
			
	 Section 10.12.
	  	Further Assurances	  	48
			
	 Section 10.13.
	  	Counterparts	  	48

  

 - iii - 

 LIST OF SCHEDULES 
  

			
	Schedule 1	  	Assigned Contracts
		
	Schedule 2	  	Licensed Patents
		
	Schedule 3	  	*** Specifications
		
	Schedule 4	  	Development Timeline
		
	Schedule 5	  	Form of Calcitonin IND Assignment
		
	Schedule 6	  	Assigned Contracts Consents
		
	Schedule 7	  	Unigene Knowledge List

 LICENSE AGREEMENT 
 This License Agreement (this “Agreement”), dated as of October 19, 2009 (the “Effective Date”), is
made by and between Unigene Laboratories Inc., a Delaware corporation with a place of business at 81 Fulton Street, Boonton, NJ 07005 USA (“Unigene”), and Tarsa Therapeutics, Inc., a Delaware corporation with a place of business at
Old City Hall, 45 School Street, Boston MA 02108 (“Tarsa”). Unigene and Tarsa are each hereinafter referred to individually as a “Party” and together as the “Parties.” 
 RECITALS 
 WHEREAS, Unigene Controls (as defined below) certain proprietary technology related to the manufacture and delivery of peptide-based drugs, including calcitonin and ***; 
 WHEREAS, the Parties have entered into that certain Contribution Agreement, dated as of the date hereof (the “Contribution
Agreement”), pursuant to which Unigene is acquiring shares of common stock of Tarsa, as provided therein; and 
 WHEREAS, pursuant to the Contribution Agreement, Unigene has agreed to grant to Tarsa certain exclusive and non-exclusive licenses to develop, test, manufacture, use and sell the Licensed Products in the Territory (each as defined
below), on the terms and conditions set forth below. 
 NOW, THEREFORE, in consideration of the mutual covenants
contained herein, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties hereby agree as follows: 
 ARTICLE I 
 DEFINITIONS 
 Section 1.1. Certain Defined Terms. The following terms shall have the meanings set forth below: 
 “Affiliate” means, with respect to a Party, any corporation, firm, limited liability company, partnership or other legal
entity that controls, is controlled by or is under common control with such Party, where “control” means, for purposes of this definition, (a) beneficial ownership of at least fifty percent (50%) of the voting securities of a
corporation or other business organization with voting securities (or such lesser percentage which is the maximum allowed by a foreign corporation in a particular jurisdiction); (b) a fifty percent (50%) or greater interest in the net
assets or profits of a partnership or other business organization without voting securities; or (c) the ability to direct the affairs of any such entity. For purposes of this Agreement, notwithstanding anything to the contrary herein, neither
Unigene nor any other shareholders of Tarsa shall be deemed to be an Affiliate of Tarsa, other than a holder of all of the outstanding capital stock of Tarsa. 
 “Agent” has the meaning set forth in Section 2.5(b). 
  

 - 2 - 

 “Agreement” has the meaning set forth in the introductory paragraph hereof.

 “Amidating Enzyme” means a recombinant enzyme used to convert non amidated peptides or proteins to amidated
peptides or proteins. 
 “Assigned Contracts” means all agreements between Unigene and a Third Party in effect
on the Effective Date that solely relate to the development of Licensed Calcitonin Products, as listed on Schedule 1, Part I, but excluding, for avoidance of doubt, those agreements listed on Schedule 1, Part II. 
 “Assigned Contract Party” means, with respect to each Assigned Contract, each Third Party counterparty and its affiliates,
if applicable, to such Assigned Contract. 
 “Assignment Agreement” has the meaning set forth in
Section 3.1(f). 
 “Bankruptcy Code” has the meaning set forth in Section 9.8.

 “Calcitonin API” means *** calcitonin or *** calcitonin. 
 “Calcitonin API Specifications” means the API Specifications, as defined in the CM Agreement. 
 “Calcitonin *** Product” means any product that comprises a Calcitonin Product and *** that is not a Calcitonin Product.

 “Calcitonin IND” means Unigene’s Investigational New Drug Application No. *** and any foreign
counterparts, including ***. 
 “Calcitonin-*** Combination Product” means a Calcitonin Combination Product
comprised of the Calcitonin Product and at least one ingredient that is a *** agent. 
 “Calcitonin Product”
means the oral drug product in development by Unigene as of the Effective Date, and ***, containing (a) Calcitonin API as its sole pharmacologically active ingredient, or (b) any *** form of Calcitonin API as its sole pharmacologically
active ingredient. 
 “CM Agreement” has the meaning set forth in Section 2.3(a). 
 “Collaboration Improvements” means all Technology and other intellectual property, whether or not patentable, that are
conceived of, discovered, developed or authored after the Effective Date (a) in the course of performing activities under, or in connection with, this Agreement by or on behalf of a Party, whether alone or together with the other Party or Third
Parties, or (b) by or on behalf of Tarsa, whether alone or together with Unigene or Third Parties, whether or not in connection with this Agreement, in each case that relate to or are an improvement to or derivative of any Licensed IP or
Confidential Information of Unigene. For purposes of this definition, a Party shall be deemed to have conceived, discovered, developed or authored Technology or any other intellectual property if at least one individual or individuals under an
obligation to assign their rights to such Technology or intellectual property to such Party and/or its Affiliates was involved in such conception, discover, development or authoring. 
  

 - 3 - 

 “Collateral Assignment” has the meaning set forth in
Section 2.5(b). 
 “Combination Product” means the Calcitonin *** Product and *** Product.

 “Commercially Reasonable Efforts” means, for each Party, the carrying out of obligations in a diligent and
sustained manner using such effort and employing such resources as would normally be exerted or employed by a similarly-situated pharmaceutical company for a product of similar market potential, and at a similar stage of its development or product
life, taking into consideration safety and efficacy, development costs, operating costs, the anticipated prescription label, the nature of the Licensed Product, the clinical setting in which it is expected to be used, competitiveness of the
marketplace, regulatory environment, the patent or other proprietary position of the Licensed Product, and other conditions then prevailing. Commercially Reasonable Efforts shall be determined country-by-country. 
 “Confidential Information” means, with respect to a Party, all proprietary or confidential information and materials
(whether or not patentable) disclosed by one Party to the other, including all trade secrets, processes, formulae, data, know-how, improvements, inventions, chemical or biological materials, assays, techniques, marketing plans, strategies, and
customer lists, regardless of whether any of the foregoing are marked “confidential” or “proprietary” or communicated to the other Party by the disclosing Party in oral, written, graphic, or electronic form. All submissions to
Regulatory Authorities, Regulatory Approvals and data that are or will be assigned to Tarsa hereunder shall be deemed Confidential Information of Tarsa. 
 “Contribution Agreement” has the meaning set forth in the recitals hereof. 
 “Control” or “Controlled” means with respect to any Technology or Patent Rights, the ownership by a Party of rights in and to such Technology or Patent Rights, or the
possession by a Party of rights under such Technology or Patent Rights, such that it has the right to grant the licenses or sublicenses to such Technology or Patent Rights as provided for herein, in each case without violating the terms of, or
increasing the amount of any payments required under (other than requiring such Party to pay the applicable Third Party a portion of any royalties, milestone payments or other consideration received by such Party (but not any upfront payments)
required to be paid by such Party to such Third Party, in accordance with the terms of the then-current arrangement or agreement between such Party and such Third Party), any arrangement or agreements between such Party and any other Person, and
with respect to such rights obtained from a third party, for as long as such rights from such third party are in effect. In the event that Unigene or any of its Affiliates is acquired by or merges with any Person, the term “Control” shall
not include any Technology or Patent Rights owned or Controlled by such Person or any of the Affiliates of such Person (other than Unigene and Unigene’s Affiliates immediately prior to such acquisition) unless such Person otherwise agrees in
writing. 
 “Cover” means, with respect to any Patent Rights, that the manufacture, use, offer for sale, sale
or import of any article or composition of matter, or the practice of any process or method, infringes at least one (1) Valid Claim of such Patent Rights. 
 “CPI” means the Consumer Price Index for All Urban Consumers (CPI-U), as published by the Bureau of Labor Statistics, U.S. Department of Labor, or any replacement index if applicable.

  

 - 4 - 

 “Development Timeline” has the meaning set forth in
Section 3.1(a). 
 “Effective Date” has the meaning set forth in the introductory paragraph hereof.

 “Effective Time” has the meaning set forth in the Assignment Agreement. 
 “EMEA” means the European Medicines Agency and any successor agency or authority thereto. 
 “FDA” means the United States Food and Drug Administration and any successor agency or authority thereto. 
 “First Commercial Sale” means, with respect to a Licensed Product, the date of the first arm’s length transaction,
transfer or disposition for value to a Third Party of such Licensed Product by or on behalf of Tarsa or any Affiliate or Sublicensee of Tarsa. 
 “Field” means all uses, including the prevention, treatment, diagnosis or control of any disease, disorder or condition in humans and animals, but excluding the Unigene Field. For the
avoidance of doubt, the Field shall include the use of all Fixed Dose Combinations of drugs other than those combinations specifically included within the Unigene Field. 
 “Fixed Dose Combination” means a fixed proportion of two (2) or more active pharmaceutical ingredients in one (1) pill, capsule, tablet or other oral preparation. 
 “FTE Rate” has the meaning set forth in Section 2.7. 
 “Gilligan” means James Gilligan, an individual employed separately by both Unigene and Tarsa on the Effective Date.

 *** 
 *** 
 *** 
 *** has the meaning set forth in Section 2.4. 
 ***
Agreement” has the meaning set forth in Section 2.4. 
 “Improvements” means, individually
and collectively, each of the Collaboration Improvements, Unigene Sole Improvements, Tarsa Sole Improvements and Joint Improvements, as the context requires. 
 “Indemnifying Party” has the meaning set forth in Section 8.4. 
 “Indemnitee” means any Person indemnified under Section 8.4. 
  

 - 5 - 

 “Intermediates” means any Calcitonin API precursors generated during the
process of manufacturing Calcitonin API. 
 “IP Term” means (a) with respect to the Calcitonin Product ***
the period commencing on the Effective Date and ending *** years after the Effective Date, and (b) with respect to Calcitonin *** Product, the period commencing on the Effective Date and ending *** years after the Effective Date. 
 “Joint Improvements” means all Technology and other intellectual property, whether or not patentable, that are conceived
of, discovered, developed or authored after the Effective Date in the course of performing activities under, or in connection with, this Agreement jointly by or on behalf of both Parties, other than the Collaboration Improvements; provided,
however, that notwithstanding the foregoing, any Technology or other intellectual property that is conceived of, discovered, developed or authored by Gilligan after the Effective Date in the course of performing activities under, or in
connection with, this Agreement, other than Collaboration Improvements, shall be deemed to be a Joint Improvement. For purposes of this definition, a Party shall be deemed to have conceived, discovered, developed or authored Technology or any other
intellectual property if at least one individual or individuals under an obligation to assign their rights to such Technology or intellectual property to such Party and/or its Affiliates was involved in such conception, discover, development or
authoring. 
 “Lending Parties” means Victory Park Management, LLC and Victory Park Special Situations Master
Fund, Ltd., and their successors and assignees under the VPC Financing Agreement. 
 “Liability” means any
debt, liability, commitment or obligation of any kind, character or nature whatsoever, whether known or unknown, secured or unsecured, accrued, fixed, absolute, potential, contingent or otherwise, and whether due or to become due, including any
liability for taxes. 
 “License” has the meaning set forth in Section 2.1. 
 “Licensed Calcitonin Formulation IP” means the Licensed Calcitonin Formulation Know-How and Licensed Calcitonin Formulation
Patent Rights. 
 “Licensed Calcitonin Formulation Know-How” means the (a) Technology Controlled by
Unigene or its Affiliates as of the Effective Date or during the IP Term that is Necessary for the development, testing, manufacture, use or sale of the Licensed Calcitonin Product and (b) the Technology comprised within the Collaboration
Improvements and the Unigene Sole Improvements, to the extent Controlled by Unigene or its Affiliates during the Term, in each case that is Necessary or useful for the development, testing, manufacture, use or sale of the Licensed Calcitonin
Product. 
 “Licensed Calcitonin Formulation Patent Rights” means (a) the Patent Rights Controlled by
Unigene or its Affiliates as of the Effective Date or during the IP Term, including those that are listed in Schedule 2 to this Agreement, that Cover the Licensed Calcitonin Product and are Necessary for the development, testing, manufacture,
use or sale of the Licensed Calcitonin Product, (b) any continuations, continuations-in-part and divisionals of such Patent Rights that are filed after the Effective Date and patents issuing from such applications, in each case to the extent
claiming priority from such Patent Rights, (c) all reissues, reexaminations, extensions and foreign counterparts of the Patent Rights specified in clauses (a) and (b) above that are issued or granted after the Effective Date and
(d) any Patent Rights Controlled by Unigene or its Affiliates during the Term that Cover the Collaboration Improvements or the Unigene Sole Improvements and which are Necessary or useful for the development, testing, manufacture, use or sale of
the Licensed Calcitonin Product. 
  

 - 6 - 

 “Licensed Calcitonin IP” means the Licensed Calcitonin Formulation IP and
the Licensed Calcitonin Manufacturing IP.” 
 Licensed Calcitonin Manufacturing IP” means the Licensed
Calcitonin Manufacturing Know-How and the Licensed Calcitonin Manufacturing Patent Rights. 
 “Licensed Calcitonin
Manufacturing Know-How” means (a) the Technology Controlled by Unigene or its Affiliates as of the Effective Date or during the IP Term that are Necessary for the manufacture of Calcitonin API, Amidating Enzyme or any Intermediates,
including the Technology licensed to *** under the *** License Agreement as of the Effective Date, at such time as such Technology becomes Controlled by Unigene during the Term, and (b) the Technology comprised within the Collaboration
Improvements or the Unigene Sole Improvements, to the extent Controlled by Unigene or its Affiliates during the Term, which are Necessary or useful for the manufacture of Calcitonin API, Amidating Enzyme or any Intermediates. 
 “Licensed Calcitonin Manufacturing Patent Rights” means (a) the Patent Rights Controlled by Unigene or its Affiliates
as of the Effective Date or during the IP Term, including those that are listed in Schedule 2 to this Agreement, including the Technology licensed to *** under the *** License Agreement as of the Effective Date, at such time as such
Technology becomes Controlled by Unigene during the Term, in each case that Cover and are Necessary for the manufacture of Calcitonin API, Amidating Enzyme or any Intermediates, (b) any continuations, continuations-in-part and divisionals of
such Patent Rights that are filed after the Effective Date and patents issuing from such applications, in each case to the extent claiming priority from such Patent Rights, (c) all reissues, reexaminations, extensions and foreign counterparts
of the Patent Rights specified in clauses (a) and (b) above that are issued or granted after the Effective Date and (d) any Patent Rights Controlled by Unigene or its Affiliates during the Term that Cover the Collaboration
Improvements or the Unigene Sole Improvements and which are Necessary or useful for the manufacture of Calcitonin API, Amidating Enzyme or any Intermediates. 
 “Licensed Calcitonin Patent Rights” means the Licensed Calcitonin Formulation Patent Rights and the Licensed Calcitonin Manufacturing Patent Rights. 
 “Licensed Calcitonin Product” means, individually and collectively, the Calcitonin Product and Calcitonin *** Product, each
in finished pharmaceutical form suitable for oral administration. 
 “Licensed IP” means the Licensed
Calcitonin IP and the Licensed *** IP. 
  

 - 7 - 

 “Licensed Patent Rights” means the Licensed Calcitonin Patent Rights and
the Licensed *** Patent Rights. 
 “Licensed Products” means the Licensed Calcitonin Product and the Licensed
*** Product. 
 “Licensed *** IP” means the Licensed *** Know-How and the Licensed *** Patent Rights.

 “Licensed *** Know-How” means (a) the Technology Controlled by Unigene or its Affiliates as of the
Effective Date or during the IP Term that is Necessary for the manufacture of ***, including the Technology licensed to *** under the *** Agreement as of the Effective Date, at such time as such Technology becomes Controlled by Unigene during the
Term, and (b) the Technology comprised within the Collaboration Improvements or the Unigene Sole Improvements, to the extent Controlled by Unigene or its Affiliates during the Term, in each case that is Necessary or useful for the manufacture
of ***. “Licensed *** Know-How” excludes the *** IP. 
 “Licensed *** Patent Rights” means
(a) the Patent Rights Controlled by Unigene or its Affiliates as of the Effective Date or during the IP Term, including those that are listed in Schedule 2 of the Agreement, and the Patent Rights licensed to *** under the *** Agreement
as of the Effective Date, at such time as such Patent Rights become Controlled by Unigene, that Cover and are Necessary for the manufacture of ***, (b) any continuations, continuations-in-part and divisionals of such Patent Rights that are
filed after the Effective Date and patents issuing from such applications, in each case to the extent claiming priority from such Patent Rights, (c) all reissues, reexaminations, extensions and foreign counterparts of the Patent Rights
specified in clauses (a) and (b) above that are issued or granted after the Effective Date and (d) any Patent Rights Controlled by Unigene and its Affiliates during the Term that Cover the Collaboration Improvements or the Unigene
Sole Improvements and which are Necessary or useful for the manufacture of ***. “Licensed *** Patent Rights” excludes the *** IP. 
 “Licensed *** Product” means, individually and collectively, the *** Product and *** Product, each in finished pharmaceutical form. 
 “Licensed Tarsa Improvements” means the Tarsa Sole Improvements Controlled by Tarsa and its Affiliates during the Term that
are Necessary for the development, testing, manufacture, use or sale of the products included in the Unigene Field. 
 “Lien” means any lien, statutory lien, pledge, mortgage, deed of trust, security interest, charge, covenant, claim, restriction, right, option, conditional sale or other title retention agreement, or encumbrance of any kind
or nature. 
 “Manufacturing Commencement Date” has the meaning set forth in Section 2.3(a).

 “Necessary” means, (a) with respect to the rights granted to Tarsa hereunder, intellectual property
that is necessary (i) to develop, test, manufacture, use or sell the Licensed Calcitonin Product as it exists on the Effective Date, to the extent necessary to obtain or maintain Regulatory Approval for such Licensed Calcitonin Product as
required by a Regulatory Authority, (ii) to develop, test, manufacture, use, sell or obtain or maintain Regulatory Approval for any Calcitonin *** Product, (iii) to manufacture *** as it is manufactured by Unigene as of the Effective Date
and (iv) to manufacture Calcitonin API as it is manufactured by Unigene as of the Effective Date and, (b) with respect to the rights granted to Unigene hereunder, intellectual property that is necessary to develop, test, manufacture, use,
sell or obtain or maintain Regulatory Approval of an oral calcitonin product in the Unigene Field. 
  

 - 8 - 

 “Net Sales” means the gross invoiced sales price for all Licensed Products
sold by Tarsa, its Affiliates or Sublicensees to unrelated Third Parties throughout the Territory, less the following customary and reasonable amounts incurred or paid by Tarsa or its Affiliates or Sublicensees with respect to sales of Licensed
Products to the extent specifically related to such Licensed Products and taken by the selling person or otherwise paid for or accrued by the selling person: (a) trade, cash and quantity discounts or rebates actually allowed or taken;
(b) credits or allowances actually given or made for rejection or return of previously sold Licensed Products or for rebates or retroactive price reductions (including Medicare, Medicaid and similar types of rebates and chargebacks);
(c) any charges for insurance, freight, and other transportation costs directly related to the delivery of Licensed Products to the extent itemized separately, included in the gross invoiced sales price and paid by the purchaser of Licensed
Products; (d) credits or allowances given or made for indigent patient programs used by Tarsa for Licensed Products; and (e) any sales and excise taxes and other taxes levied on or measured by the billing amount, other than franchise or
income tax of any kind whatsoever. Such amounts shall be determined from the books and records of Tarsa, which shall be maintained in accordance with United States generally accepted accounting principles. 
 Notwithstanding the foregoing, the following shall not be included in Net Sales: (1) Tarsa’s or any of its Affiliates’ or
Sublicensee’s transfer of Licensed Products to another Tarsa Affiliate that are subsequently sold to unrelated Third Parties, (2) Licensed Products provided by Tarsa or its Affiliates for administration to patients enrolled in clinical
trials or distributed through a not-for-profit foundation at no charge to eligible patients, provided that Tarsa, its Affiliates and Sublicensees receive no consideration from such clinical trials or not-for-profit foundation for such use of
Licensed Products and (3) Licensed Products used as samples to promote additional Net Sales, in amounts consistent with normal business practices in the industry for similar products with similar indications. 
 Notwithstanding the foregoing, in the event a Licensed Product is sold as a Combination Product in a country, Net Sales shall be calculated
by multiplying the Net Sales of the Combination Product by the fraction A/(A+B), where A is the gross invoice price of the Licensed Product when sold separately in such country, and B is the gross invoice price of the other clinically active
prophylactic or therapeutic product(s) included in the Combination Product when sold separately in such country. In the event no such separate sales are made by Tarsa or its Affiliates or Sublicensees in such country, Net Sales of the Combination
Product shall be calculated in a manner to be negotiated and agreed upon by the Parties, reasonably and in good faith, prior to any sale of such Combination Product, which shall be based upon the respective cost of goods sold of the active
components of such Combination Product. 
 *** has the meaning set forth in Section 2.3(a). 
  

 - 9 - 

 *** Drug Products” has the meaning set forth in the *** License Agreement.

 *** License Agreement” has the meaning set forth in Section 2.3(a). 
 “Party” and “Parties” have the meaning set forth in the introductory paragraph hereof. 
 “Patent Rights” means all rights arising under patents or patent applications (including any patents issuing therefrom), as
well as any continuations, continuations-in-part, divisionals thereof and all reissues, reexaminations and extensions thereof. 
 “Person” means an individual, partnership, joint venture, corporation, limited liability company, trust, unincorporated organization or other similar entity or governmental authority. 
 *** means ***. 
 *** Product” means any product that comprises a *** Product and at least *** that is not a *** Product. 
 *** means a product that (a) contains *** supplied by Unigene or manufactured by Tarsa or its Affiliates or Sublicensees under the license granted in Section 2.1 and (b) is administered using the *** licensed
from ***. 
 *** Specifications” means the *** specifications attached hereto as Schedule 3. 
 *** has the meaning set forth in Section 3.1(h). 
 *** License Agreement” has the meaning set forth in Section 3.1(h). 
 *** License” has the meaning set forth in Section 2.1. 
 *** Patents” has the meaning set forth in Section 2.1. 
 “Regulatory Approvals” means the technical, medical and scientific licenses, registrations, authorizations and approval
required for the manufacture, use, storage, import, transport, marketing, promotion, selling, and placing on the market of a Licensed Product approved by any Regulatory Authority in the Territory. This includes any authorization necessary for the
development, manufacture, distribution, marketing, promotion, offer for sale, use, import, export or sale of the Licensed Products within the Territory. 
 “Regulatory Authority” means any government authority or agency charged with issuing approvals, licenses, registrations or authorizations necessary for the manufacture, use, storage,
import, transport, marketing, promotion, selling, and placing on the market of a Licensed Product in a country in the Territory. 
 “Regulatory Materials” means all regulatory submissions and applications, Regulatory Approvals, minutes of meetings with Regulatory Authorities, data arising out of pre-clinical and clinical development activities and any
other information, documentation, data or materials necessary for obtaining or maintaining Regulatory Approvals, in each case regarding the Calcitonin Product that is a Licensed Calcitonin Product. 
  

 - 10 - 

 “Relinquishing Party” has the meaning set forth in
Section 7.2(c). 
 “Right of Reference” has the meaning set forth in 21 C.F.R. § 314.3(b) and
any foreign counterpart to such regulation. 
 “ROFO/ROFR Agreement” has the meaning set forth in
Section 2.5(b). 
 “Royalty-Bearing Licensed *** Product” shall have the meaning set forth in
Section 4.2(c). 
 “Salmon Calcitonin Materials” means, individually and collectively, the API
(“Salmon Calcitonin API”), Intermediate and Amidating Enzyme, as each such term is defined in the *** License Agreement. 
 “Sandoz” has the meaning set forth in Section 2.3(a). 
 “Sandoz Agreement” has the meaning set forth in Section 2.3(h). 
 “SEC”
has the meaning set forth in Section 5.1. 
 “Sublicense” means each sublicense agreement entered
into by Tarsa pursuant to Section 2.5. 
 “Sublicensee” means any Third Party or Affiliate of Tarsa
to whom Tarsa grants a Sublicense of the rights granted to Tarsa under this Agreement, as provided under Section 2.5. 
 “Tarsa” has the meaning set forth in the introductory paragraph hereof. 
 “Tarsa Sole
Improvements” means all Technology and other intellectual property, whether or not patentable, that are conceived of, discovered, developed or authored after the Effective Date in the course of performing activities under, or in connection
with, this Agreement, solely by or on behalf of Tarsa, whether alone or together with Third Parties, other than the Collaboration Improvements. For purposes of this definition, Tarsa shall be deemed to have conceived, discovered, developed or
authored Technology or any other intellectual property if at least one individual or individuals under an obligation to assign their rights to such Technology or intellectual property to Tarsa and/or its Affiliates was involved in such conception,
discover, development or authoring. 
 “Tarsa Indemnitees” has the meaning set forth in
Section 8.4(a). 
 “Technology” means all cell lines, cell banks, clones, vectors, cassettes,
separations, purifications, ideas, inventions, discoveries, biologic materials, data, instructions, formulae, designs, specifications, methods, processes, formulations, techniques, know-how, technical information (including structural and functional
information), manufacturing process information, pre-clinical information, clinical information, and any and all proprietary biological, chemical, pharmacological, physical, analytical, toxicological, pre-clinical, clinical, assay, safety, control
and manufacturing data and materials. For avoidance of doubt, Technology does not include any trademarks, software or information technology systems. 
  

 - 11 - 

 “Term” has the meaning set forth in Section 9.1. 
 “Territory” means worldwide, excluding the People’s Republic of China. 
 “Third Party” means any Person other than Tarsa, Unigene and their respective Affiliates. 
 “Unigene” has the meaning set forth in the introductory paragraph hereof. 
 “Unigene-Controlled Patent Rights” has the meaning set forth in Section 7.2(b). 
 “Unigene Drug Product” has the meaning set forth in the *** License Agreement. 
 “Unigene Field” means the development and commercialization of any calcitonin product in *** with one (1) or more ***
or analogs or derivatives thereof, in each case for the ***. 
 “Unigene Indemnitees” has the meaning set forth
in Section 8.4(b). 
 “Unigene Patent Rights” has the meaning set forth in the *** License
Agreement; provided that, at such time that Unigene Controls the Patent Rights included within such definition, such Patent Rights shall cease to be considered Unigene Patent Rights and, to the extent they would be Licensed Calcitonin Manufacturing
Patent Rights, shall be considered Licensed Patent Rights hereunder. 
 “Unigene’s Knowledge” means the
actual knowledge of the individuals listed on Schedule 7 as of the Effective Date. 
 “Unigene’s Oral
Product” has the meaning set forth in the *** License Agreement. 
 “Unigene Sole Improvements” means
all Technology and other intellectual property, whether or not patentable, that are conceived of, discovered, developed or authored after the Effective Date in the course of performing activities under, or in connection with, this Agreement solely
by or on behalf of Unigene, whether alone or together with Third Parties, other than Collaboration Improvements. For purposes of this definition, Unigene shall be deemed to have conceived, discovered, developed or authored Technology or any other
intellectual property if at least one individual or individuals under an obligation to assign their rights to such Technology or intellectual property to Unigene and/or its Affiliates was involved in such conception, discover, development or
authoring. 
 “Valid Claim” means a claim in an unexpired and issued patent or pending patent application that
has not been disclaimed, revoked or held invalid or unenforceable by a final unappealable decision of a government agency or court of competent jurisdiction, or unappealed within the time limit allowed for appeal, or which has not been admitted to
be invalid or unenforceable through reissue, reexamination or disclaimer or otherwise; provided that, on a country-by-country basis, a patent application pending for more than *** years from the date of filing of such application as a utility,
non-provisional application shall not be considered to have any Valid Claim for purposes of this Agreement from and after such *** year date unless and until a patent with respect to such application issues. 
  

 - 12 - 

 “VPC Financing Agreement” means the Financing Agreement, dated as of
September 30, 2008, by and among Unigene and the Lending Parties (as amended, supplemented, restated or otherwise modified from time to time). 
 Section 1.2. Rules of Construction and Interpretation. 
 (a) The
definitions of the terms herein shall apply equally to the singular and plural forms of the terms defined. Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms. The words
“include”, “includes” and “including” shall be deemed to be followed by the phrase “without limitation”. The word “will” shall be construed to have the same meaning and effect as the word
“shall”. The word “any” means “any and all” unless otherwise clearly indicated by context. “$” as used in this Agreement means the lawful currency of the United States. Where either Party’s consent is
required hereunder, except as otherwise specified herein, such Party’s consent may be granted or withheld in such Party’s sole discretion. 
 (b) Unless the context requires otherwise, (i) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or
other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein or therein), (ii) any reference to any laws herein shall be construed
as referring to such laws as from time to time enacted, repealed or amended, (iii) any reference herein to any Person shall be construed to include the Person’s successors and assigns, (iv) the words “herein”,
“hereof” and “hereunder”, and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof, and (v) all references herein to Articles, Sections or
Schedules, unless otherwise specifically provided, shall be construed to refer to Articles, Sections and Schedules of this Agreement. 
 ARTICLE II 
 GRANT OF RIGHTS 
 Section 2.1. License to Tarsa. Subject to the terms and conditions of this Agreement, including the performance of Tarsa’s
payment obligations hereunder, Unigene grants to Tarsa, and Tarsa accepts, during the Term the following licenses (the “License”): 
 (a) a royalty-bearing, non-transferable (except as set forth in Section 10.7), sublicenseable (to the extent permitted by Section 2.5) and exclusive *** license, under the Licensed
Calcitonin Formulation IP and Unigene’s interest in the Joint Improvements, solely to research, develop, use, sell, offer for sale, import and otherwise commercialize the Licensed Calcitonin Products in the Field in the Territory,
provided that the license granted under this Section 2.1(a) does not include the right to manufacture or have manufactured Calcitonin API, which rights are granted under Section 2.1(b); 
 (b) subject to Section 2.3, a royalty-bearing, non-transferable (except as set forth in Section 10.7),
sublicenseable (to the extent permitted by Section 2.5) and co-exclusive license with Unigene, under the Licensed Calcitonin Manufacturing IP and Unigene’s interest in the Joint Improvements, to manufacture and have manufactured
Calcitonin API, Amidating Enzyme and Intermediates anywhere in the Territory solely for use in the Licensed Calcitonin Products licensed under Section 2.1(a) above that are researched, developed or commercialized by Tarsa, its Affiliates
or sublicensees; 
  

 - 13 - 

 (c) subject to Section 2.4, a royalty-bearing, non-transferable (except as set
forth in Section 10.7), sublicenseable (to the extent permitted by Section 2.5) and non-exclusive license, under the Licensed *** IP and Unigene’s interest in the Joint Improvements, solely to manufacture and have
manufactured Licensed *** Products in the Territory; and 
 (d) a royalty-free, non-transferable (except as set forth in
Section 10.7), sublicenseable (to the extent permitted by Section 2.5) and non-exclusive license under the *** solely to research, develop, manufacture, have manufactured, use, sell, offer for sale, import and otherwise
commercialize Licensed *** Products in the Field in the Territory. 
 Notwithstanding anything to the contrary herein, Unigene
reserves all rights in and to, and Tarsa receives no license hereunder to, the Licensed IP in the Unigene Field, and except as expressly provided hereunder, Unigene reserves all rights in and to the Licensed IP. For avoidance of doubt, Tarsa’s
rights under Section 2.1(c) to manufacture and have manufactured *** are granted only with respect to the right to manufacture or have manufactured *** for use in the Licensed *** Product in the Field in the Territory. No license is
granted by Unigene hereunder with respect to any Patent Rights or Technology that cover any therapeutic, prophylactic or diagnostic ingredient or component other than Calcitonin API and ***, and no license is granted by Unigene hereunder with
respect to any *** other than ***. 
 Tarsa shall not use the Licensed IP for any purpose except as expressly set forth in this
Agreement. Tarsa’s rights under the License are limited to the Territory, and Tarsa shall not, directly or indirectly, (i) seek customers for any Licensed Product outside the Territory, (ii) sell any Licensed Product to customers
outside of the Territory or market or sell any Licensed Product for use in the Unigene Field, (iii) sell any Licensed Product to customers within the Territory or in the Field if Tarsa knows or believes that such customers will sell, ship or
otherwise distribute any Licensed Product to jurisdictions outside of the Territory or use any Licensed Product in the Unigene Field or (iv) otherwise establish a distribution or sales network for any Licensed Product outside the Territory.
Likewise, Unigene shall not, directly or indirectly, (A) seek customers for any Licensed Product inside the Territory other than in the Unigene Field, (B) sell any Licensed Product to customers inside of the Territory, other than in the
Unigene Field, or market or sell any Licensed Product for use in the Field, (C) sell any Licensed Product to customers outside the Territory or in the Unigene Field if Unigene knows or believes that such customers will sell, ship or otherwise
distribute any Licensed Product to jurisdictions inside of the Territory to use any Licensed Product in the Field or (D) otherwise establish a distribution or sales network for any Licensed Product inside the Territory, other than in the
Unigene Field. Notwithstanding anything to the contrary herein, Tarsa’s rights under the License to any Patent Rights included in the Licensed IP that derive from the license to certain patents (the *** Patents”) granted to Unigene
by the *** (the *** License”) shall be non-exclusive and are limited to the United States. 
  

 - 14 - 

 Section 2.2. License to Unigene. Subject to the terms and conditions of this
Agreement, Tarsa grants to Unigene, and Unigene accepts, during the Term, (a) a non-exclusive, royalty-free, worldwide, non-transferable (except as set forth in Section 10.7), sublicenseable (to the extent permitted by
Section 2.5(c)) license under the Licensed Tarsa Improvements and Tarsa’s interest in the Joint Improvements solely to research, develop, manufacture, have manufactured, use, sell, offer for sale, import and otherwise commercialize
products in the Unigene Field, and (b) a non-exclusive, non-transferable (except as set forth in Section 10.7), non-sublicenseable (except as permitted by Section 2.5(c)) and royalty-free license under each of the rights
exclusively licensed to Tarsa under Section 2.1, solely to perform its obligations under this Agreement. 
 Section 2.3. Manufacturing of Calcitonin API. 
 (a) ***. Accordingly, Tarsa agrees that the license
granted pursuant to Section 2.1(b) shall not be effective with respect to the Salmon Calcitonin Materials until, and Tarsa shall not manufacture or have manufactured any Salmon Calcitonin Materials under this Agreement, nor shall Tarsa
exercise any rights granted to it hereunder with respect to the Licensed Calcitonin Manufacturing IP relating to the Salmon Calcitonin Materials, until *** (each such date, the “Manufacturing Commencement Date”). ***.
Notwithstanding the foregoing, Tarsa shall not be precluded under this Agreement from entering into a direct supply agreement for Salmon Calcitonin API with Sandoz for use in the Licensed Calcitonin Product (the “Sandoz Agreement”).
Tarsa shall use Commercially Reasonable Efforts to provide that the Sandoz Agreement shall (i) protect the confidentiality of all Unigene Confidential Information that may be disclosed to or used by Sandoz or Tarsa on terms at least as
protective as those set forth in the CM Agreement, (ii) preserve for Unigene ownership of any improvements made in connection with the Sandoz Agreement that would be owned by Unigene if made under the CM Agreement, (iii) preserve for
Unigene license rights to improvements made in connection with the Sandoz Agreement that would be licensed to Unigene if made under the CM Agreement, and (iv) provide that Tarsa has assumed Unigene’s minimum purchase obligations under
Section 4(3) of the CM Agreement. Tarsa will provide Unigene with a copy of the proposed Sandoz Agreement, in substantially final form, and Unigene shall have *** to review such proposed Sandoz Agreement and to provide Tarsa with comments with
respect to the matters addressed in the foregoing, which comments Tarsa shall duly and reasonably consider and discuss with Unigene, but shall thereafter be free to accept or reject such comments in its sole discretion. Until the
Manufacturing Commencement Date, unless Tarsa has entered into the Sandoz Agreement, Tarsa shall order all of its requirements for Salmon Calcitonin API for use in the Licensed Calcitonin Product from Sandoz through Unigene, to the extent required
by and subject to the terms of this Section 2.2 and the CM Agreement. 
 (b) Tarsa shall submit forecasts and firm
orders for Salmon Calcitonin API to Unigene pursuant *** acknowledges and agrees that such forecasts and orders shall be binding upon Tarsa in the manner specified in the CM Agreement. ***. 
 (c) The prices charged to Tarsa by Unigene for Salmon Calcitonin API shall be ***. 
  

 - 15 - 

 (d)***. 
 (e) Unigene shall have no liability or responsibility for any Salmon Calcitonin API ordered by or delivered to Tarsa, other than to submit Tarsa’s forecasts and orders for Salmon Calcitonin API to
Sandoz, provided that (i) Unigene shall be liable for any failure to accurately and correctly perform analysis of samples for compliance with the Calcitonin API Specifications, provided that, in the event of a dispute between Unigene and
Tarsa regarding such analysis, the accuracy and correctness of such analysis shall be determined in accordance with the procedures outlined in Section 22(4) of the CM Agreement (with Tarsa having the same rights under this Agreement as Unigene
has under the CM Agreement), ***. Upon Tarsa’s receipt of Regulatory Approval by the FDA or EMEA for the Licensed Calcitonin Product, Tarsa shall be required, unless otherwise agreed to by the Parties, to purchase a minimum quantity of *** of
Salmon Calcitonin API per calendar year or pay the corresponding amount to Unigene for payment to Sandoz to the extent required by the CM Agreement. 
 (f)***. 
 (g) Unigene agrees that during the Term: 
 (i) Unigene shall use Commercially Reasonable Efforts to fulfill its obligations under the CM Agreement to the extent that failure to do so
would adversely affect Tarsa or its rights hereunder, except where due to an act or omission of Tarsa; 
 (ii) Unigene shall
not enter into any subsequent agreement with Sandoz that modifies or amends the CM Agreement in any way that would materially and adversely affect Tarsa’s rights or economic interest under this Agreement without Tarsa’s prior written
consent, and shall provide Tarsa with a copy of all modifications to or amendments of the CM Agreement, regardless of whether Tarsa’s consent was required with respect thereto; 
 (iii) Unigene shall not terminate the CM Agreement in whole or in part, directly or indirectly, without Tarsa’s prior written consent
if such termination would materially and adversely affect Tarsa’s license granted hereunder; 
 (iv) Unigene shall
promptly furnish Tarsa with copies of all material communications Unigene receives from Sandoz under the CM Agreement that directly relate to the supply of Salmon Calcitonin API to Tarsa pursuant to this Agreement, except where such disclosure is
prohibited by the CM Agreement, in which case Unigene shall seek from Sandoz permission to make such disclosure to Tarsa; 
 (v) Unigene shall promptly furnish Tarsa with copies of all material reports and other communications that Unigene furnishes to Sandoz that directly relate to the supply of Salmon Calcitonin API to Tarsa pursuant to this Agreement; and

 (vi) Unigene shall furnish Tarsa with copies of all notices received by Unigene relating to any alleged breach or default by
Unigene under the CM Agreement within *** business days after Unigene’s receipt thereof and, if Unigene cannot or chooses not to cure or otherwise resolve any such alleged breach or default, Unigene shall so notify Tarsa within *** business
days thereafter. 
  

 - 16 - 

 (h) Notwithstanding anything to the contrary contained in this Agreement, the terms of
Section 2.2(b) through Section 2.2(g) shall be in effect only until Tarsa enters into the Sandoz Agreement. Upon the execution of the Sandoz Agreement, Tarsa shall no longer be obligated to order any of its requirements for
Salmon Calcitonin API through Unigene and neither Party shall be thereafter required to comply with any provisions in Section 2.2(b) through Section 2.2(g). However, following the execution of the Sandoz Agreement, the
provisions of Section 2.2(a) shall remain in effect. 
 (i) ***. 
 (j) Tarsa acknowledges that neither Sandoz nor Unigene currently manufactures or has any plan to manufacture Calcitonin API that is ***.
Accordingly, if Tarsa wishes to have such *** manufactured and supplied by Unigene pursuant to this Agreement, Tarsa shall so notify Unigene in writing and the Parties shall discuss and negotiate in good faith any additional terms or conditions
necessary for the manufacture and supply by Unigene of such *** calcitonin. 
 Section 2.4. Licensed *** Product.

 (a) Tarsa acknowledges that Unigene has entered into a license agreement with ***, dated *** (the *** Agreement”)
pursuant to which Unigene has licensed *** certain intellectual property rights relating to ***. *** Section 2.1(c). The license granted under Section 2.1(c) shall not be effective, and Tarsa shall not exercise any rights
granted under Section 2.1(c) or any other rights hereunder with respect to the Licensed *** IP, until Unigene provides Tarsa with written notice that ***. 
 (b) Subject to this Section 2.4(b), Unigene shall supply such reasonable quantities of *** in bulk form either out of its inventory of *** existing at the Effective Date or manufactured by
Unigene for Tarsa, at Tarsa’s sole discretion, as shall be reasonably requested by Tarsa from time to time solely for Tarsa’s use in research and development of the Licensed *** Product through clinical trials. Tarsa agrees that if it uses
the *** supplied by Unigene for any purpose other than in the research and development of the Licensed *** Product, then *** shall have the right to enforce this Section 2.4(b) of this Agreement on behalf of Unigene with respect to such
misuse of the *** supplied by Unigene. Such ***, if ordered from Unigene’s inventory, shall be delivered to Tarsa within *** days of Unigene’s receipt of Tarsa’s written order therefor, and shall be shipped FOB, Unigene’s
facility. If Tarsa requests that *** be manufactured by Unigene, the Parties shall first enter into negotiations to agree upon lead times, delivery schedules, minimum purchase requirements and other matters relevant to Unigene’s manufacture of
*** pursuant to this Section 2.4(b). All *** supplied by Unigene to Tarsa under this Agreement shall comply in all material respects with the *** Specifications, Current Good Manufacturing Practices as defined in 21 CFR § 210 et
seq. and applicable law. Unigene shall provide Tarsa with certificates of analysis, certificates of compliance and documentation of storage conditions for any *** supplied to Tarsa under this Section 2.4(b). The purchase price for ***
shall be *** per gram from Unigene’s inventory. For *** Unigene manufactures for Tarsa pursuant to this Section 2.4(b), the purchase price shall be equal to ***; provided, however, that such purchase price shall in no
event, during the *** after the Effective Date, ***, Unigene shall not be required to manufacture *** for Tarsa unless Tarsa agrees to pay ***. Payment shall be made within *** days following receipt of any shipment of *** to Tarsa; provided
that such shipment has been accompanied by an invoice for the purchase price and provided further that Tarsa has not rejected the *** in such shipment, which Tarsa may do only in writing within *** days of receipt of such shipment and only if such
shipment does not comply in all material respects with the *** Specifications. At Tarsa’s request made at any time, Tarsa and Unigene shall, in good faith, enter into negotiations for a *** supply agreement. 
  

 - 17 - 

 Section 2.5. Right to Sublicense. 
 (a) Tarsa may sublicense any of the rights granted to it hereunder to any Affiliate or Third Party, including the right to grant further
sublicenses, subject to compliance with the terms of this Agreement, except that Tarsa shall not sublicense the technologies described in, or any rights granted hereunder with respect to, the *** Patents except to the extent permitted by the ***
License. Not later than *** days prior to granting any Sublicense of its rights under this Agreement to an Affiliate or Third Party, Tarsa shall provide Unigene with a true and correct copy of the proposed Sublicense agreement for Unigene’s
review, and Tarsa shall reasonably consider any comments provided by Unigene with respect to such Sublicense agreement; provided, however, that Tarsa shall be permitted to accept or reject any such comments in its sole discretion.

 (b) Each Sublicense granted by Tarsa to a permitted Sublicensee pursuant to this Section 2.5 shall be subject and
subordinate to the terms and conditions of this Agreement and shall contain terms and conditions consistent with those in this Agreement and shall not in any way diminish, reduce or eliminate any of Tarsa’s obligations under this Agreement.
Without limiting the foregoing, each Sublicense agreement with a permitted Sublicensee shall be in writing and shall contain the following provisions: (i) a requirement that such Sublicensee submit applicable sales or other reports consistent
with the requirements of this Agreement, (ii) a requirement to keep books and records, and to permit Unigene and any licensor to Unigene to audit (either directly or through an independent auditor) such books and records, consistent with the
requirement of this Agreement, (iii) a requirement that such Sublicensee comply with the confidentiality provisions of this Agreement, (iv) a requirement to comply with all other applicable terms of this Agreement, including complying with
Unigene’s *** under Section 3.1(a), (v) a requirement that each Sublicensee allow Tarsa and Unigene to inspect its facilities upon reasonable notice consistent with the compliance of the terms and conditions of this Agreement,
(vi) a provision specifying that Unigene shall be a third party beneficiary of such Sublicense agreement with the independent right to enforce its terms against the Sublicensee to the extent reasonably necessary to protect Unigene’s rights
and (vii) a provision whereby such Sublicensee acknowledges that this Agreement and such Sublicense are subject to the terms and conditions of (A) that certain Collateral Assignment of Agreement, dated as of the Effective Date, by and
between Victory Park Management, LLC (“Agent”) and Unigene (as amended, restated, modified or supplemented from time to time, the “Collateral Assignment”) and (B) that certain ROFO/ROFR Agreement, dated as of
the Effective Date, by and among Tarsa, Agent, and the “Investors” party thereto (as amended, restated, modified or supplemented from time to time, the “ROFO/ROFR Agreement”). Tarsa shall provide Unigene with a copy of
each such executed Sublicense agreement within thirty (30) days after the execution thereof; provided that any such copy may be redacted by Tarsa to the extent that any such redaction does not impair Unigene’s ability to ensure compliance
with this Agreement. Tarsa shall diligently enforce compliance by each of its Sublicensees with the applicable Sublicense agreement. Any act or omission of a Sublicensee shall be deemed an act or omission of Tarsa under this Agreement. If Tarsa
discovers that a Sublicensee has taken any action or failed to take any action that would, if done so by Tarsa, constitute a breach of this Agreement that continues beyond all applicable grace periods, Tarsa promptly shall notify Unigene thereof,
and in addition to taking all actions reasonably necessary to cause the cessation of such breach, Tarsa shall take such remedial action as may be reasonably requested by Unigene, including termination of such Sublicensee’s agreement as
reasonably requested by Unigene. 
  

 - 18 - 

 (c) Unigene may sublicense any of the rights granted to it hereunder to any Affiliate or
Third Party, including the right to grant further sublicenses, provided that not later than *** days prior to granting any sublicense of its rights under this Agreement to an Affiliate or Third Party, Unigene shall provide Tarsa with a true and
correct copy of the proposed sublicense agreement for Tarsa’s review, and Unigene shall reasonably consider any comments provided by Tarsa with respect to such sublicense agreement; provided, however, that Unigene shall be
permitted to accept or reject any such comments in its sole discretion. 
 (d) Notwithstanding anything to the contrary in this
Agreement, neither Tarsa nor any of its Affiliates or Sublicensees may sublicense or otherwise convey any rights to or under the Licensed Calcitonin IP to *** or any of *** affiliates for or in connection with any *** Drug Product. 
 Section 2.6. Marking. Tarsa shall label or mark each Licensed Product or the Licensed Product container or package with the
patent number or numbers of any issued or pending Licensed Patent Rights that Cover the Licensed Product. The content, form, location and language used for such marking shall be in accordance with the laws and practices of each country in which the
Licensed Products are sold or the patents have issued or are pending. 
 Section 2.7. R&D Services. Unigene
shall use Commercially Reasonable Efforts to provide all research, development, technology transfer and other services relating to the Licensed Products that are agreed to by the Parties pursuant to a written statement of work, as described below,
and Tarsa shall pay Unigene ***, for this assistance. If at any time Tarsa desires that Unigene perform such services, including technology transfer services relating to the Licensed Calcitonin Manufacturing IP when the Manufacturing Commencement
Date shall have occurred, the Parties shall in good faith negotiate one or more statements of work that set forth the details of the services that would be provided by Unigene, including a description and scope of the particular services to be
provided by Unigene, the desired timeframe for such services and the necessary materials and equipment and personnel resources. Unigene shall not be required to provide any such services until the execution of such statement of work by both Parties,
unless otherwise required by the terms of this Agreement. All such statements of work shall include a reference to this Agreement and upon execution by both Parties shall become an integral part of, and subject to the terms of, this Agreement. In
the event of any conflict between the terms of a statement of work and the terms of this Agreement, the terms of this Agreement shall control. Unless otherwise specifically agreed in a statement of work, all services provided by Unigene to Tarsa
under a statement of work shall be provided at a rate of *** per person-year (“FTE Rate”), plus reimbursement of Unigene’s reasonable out-of-pocket Third Party costs and expenses. The FTE Rate shall be ***, and (b)***. Unigene
shall keep and maintain timesheets and formal documentation for all work to be reimbursed by Tarsa at the FTE Rate. 
  

 - 19 - 

 Section 2.8. Additional Services. Unigene agrees and acknowledges that Tarsa
will hire Gilligan on the Effective Date as Chief Scientific Officer of Tarsa, and initially Tarsa intends to employ Gilligan on a part-time basis of *** of his normal working hours (based on an eight (8) hour work day, Monday through Friday,
excluding holidays and vacation time), and that such employment shall not violate Section 2.9 hereof. Tarsa shall be directly responsible to Gilligan for payment of Gilligan’s salary based on his employment with Tarsa. Unigene
hereby waives any provision of any agreement between Gilligan and Unigene that would preclude Gilligan from being an employee of Tarsa, including, without limitation, any non-compete provisions of any such agreements. Any employment agreement
between Tarsa and Gilligan shall contain a provision pursuant to which Gilligan shall agree not to disclose to Tarsa any confidential information of Unigene or any Third Party with respect to which Gilligan has an obligation to Unigene or such Third
Party not to disclose, nor shall Tarsa request Gilligan to disclose such information. Any Improvements made by or contributed by Gilligan while employed by or acting as a consultant of Tarsa shall be owned by the Parties in accordance with the terms
of this Agreement. This Section 2.8 is not an agreement for joint employment; the Parties agree that Gilligan shall be employed separately by each Party and that each Party is separately liable for any obligations arising out of that
Party’s employment of Gilligan. 
 Section 2.9. Non-Solicitation. During the Term and for *** years thereafter,
neither Party shall solicit for employment any employees of the other Party. For the purposes of this Section 2.9, “solicit” shall mean that a Party shall not initiate any contact or communication for the purpose of inviting or
requesting any of the other Party’s employees to become employed by such Party. The foregoing shall not limit a Party’s right to advertise job openings in public media. 
 Section 2.10. Useful Improvements. 
 (a) During the IP Term, if Unigene shall Control any rights to Technology or Patent Rights that would be useful for the development, testing, manufacture, use, sale or other commercialization of a
Licensed Product and which rights are not included in the license granted to Tarsa under Section 2.1, Unigene promptly shall notify Tarsa thereof in writing. If Tarsa wishes to obtain a license to any such Technology or Patent Rights,
Tarsa shall notify Unigene thereof in writing and the Parties agree to engage in good faith negotiation, not to exceed ninety (90) days after receipt of Unigene’s notice unless otherwise mutually agreed to by the Parties, of commercially
reasonable terms upon which Unigene would license such Technology or Patent Rights to Tarsa for use with the applicable Licensed Product in the Field in the Territory. 
 (b) During the period that is *** years after the Effective Date, if Tarsa shall Control any rights to any Tarsa Sole Improvement that would be useful for the development, testing, manufacture, use, sale
or other commercialization of products in the Unigene Field and which rights are not included in the license granted to Unigene under Section 2.2, Tarsa promptly shall notify Unigene thereof in writing. If Unigene wishes to obtain a
license to any such Tarsa Sole Improvement, Unigene shall notify Tarsa thereof in writing and the Parties agree to engage in good faith negotiation, not to exceed *** days after receipt of Tarsa’s notice unless otherwise mutually agreed to by
the Parties, of commercially reasonable terms upon which Tarsa would license such Tarsa Sole Improvement to Unigene for use with products in the Unigene Field. 
  

 - 20 - 

 ARTICLE III 
 DEVELOPMENT AND COMMERCIALIZATION 
 OF LICENSED
PRODUCTS 
 Section 3.1. Commercialization. 
 (a) Tarsa shall be fully responsible for, and shall have full control and authority over, the research, development and commercialization of
the Licensed Products and all costs and expenses related thereto, including (i) all activities related to human clinical trials, including the proposed Phase III oral calcitonin clinical trial at all sites, (ii) subject to
Section 2.3 and Section 2.4, all activities relating to manufacture and supply of all Licensed Products and (iii) all activities relating to any regulatory filings, registrations, applications and Regulatory Approvals
relating to any of the foregoing, in each case in accordance with the Development Timeline. Notwithstanding the foregoing, until such time as Unigene assigns to Tarsa each Calcitonin IND and the Assigned Contracts in accordance with the terms
hereof, Unigene shall take all actions in connection with the development of the Licensed Calcitonin Products, including conducting clinical trials and interactions with Regulatory Authorities (which, in the case of correspondence, shall be subject
to Tarsa’s prior approval or, in the case of meetings, shall include Tarsa representatives as attendees), as may be reasonably requested by Tarsa at Tarsa’s direction and expense (including payment to Unigene at the FTE Rate for work
performed by Unigene and reimbursement of Unigene’s reasonable out-of-pocket expenses); provided that, Unigene shall not be required without its consent to take actions pursuant to this sentence for a period longer than *** days from the
Effective Date. The “Development Timeline,” which is attached to this Agreement as Schedule 4 and made an integral part hereof and which may be amended as set forth in this Agreement, sets forth the following timelines for
development and commercialization of a Licensed Calcitonin Product: (A) completion of the proposed ***; (B) filing of ***; (C) obtaining of ***; (D) Tarsa’s identification of and ***; and (E) if Tarsa elects not to ***.
Tarsa shall own all applications for Regulatory Approval filed by Tarsa or its Sublicensees and all Regulatory Approvals issuing therefrom for the Licensed Products and all data associated therewith. Unigene shall have a *** with respect to the
following data and information included in all *** and *** for the Licensed Calcitonin Products obtained or submitted by Tarsa or any Sublicensee and any other *** made by Tarsa or any Sublicensee with respect to the Licensed Calcitonin Products,
solely for the purpose of obtaining *** for *** in the *** data. Tarsa promptly will provide, and cause its Sublicensees to provide, a signed statement to effect this ***, if requested by Unigene, in accordance with *** or any foreign counterpart to
such ***. 
  

 - 21 - 

 (b) Diligence. Tarsa shall exercise Commercially Reasonable Efforts in evaluating,
developing and commercializing the Licensed Calcitonin Products in the Field in the Territory, and in fulfilling its obligations under the Development Timeline, as such may be amended based on the occurrence of an External Factor, as defined below,
in accordance with this Section 3.1(b). Tarsa agrees that failure to fulfill its obligation under this Section 3.1(b) will constitute a material breach of this Agreement, except to the extent caused by Unigene’s failure
to provide any services required to be provided by Unigene pursuant to a statement of work entered into by the Parties pursuant to Section 2.7 or to comply with any of its obligations under this Agreement. Each date indicated in the
Development Timeline (and any subsequent dates) shall be extended automatically to reflect any delay in the achievement of the applicable event attributable to External Factors. For purposes of this Section 3.1(b), an “External
Factor” shall mean that one or more of the following events or circumstances has occurred in development, manufacturing or regulatory conditions relating to a Licensed Calcitonin Product that delays the further development of such Licensed
Calcitonin Product or results in delayed achievement of the applicable event; provided that (i) such events or circumstances were not caused by the negligent, intentional or fraudulent act or omission of Tarsa or any of its Affiliates or
Sublicensees and (ii) Tarsa or its Affiliates or Sublicensees have taken all Commercially Reasonable Efforts to overcome such events or circumstances: (A) ***, if prepared and submitted in accordance with all applicable laws, rules and
regulations, *** outside the United States; (B) *** a Licensed Calcitonin Product ***, or by or on behalf of Tarsa or its Affiliates or Sublicensees reasonably based on ***, or by Tarsa’s reasonable *** Licensed Calcitonin Product;
(C) ***, as specified in the applicable *** for the Licensed Calcitonin Product; (D) receipt of *** Licensed Calcitonin Product; (E) decisions, communications *** the Licensed Calcitonin Product that ***, including *** the Licensed
Calcitonin Product ***; (F) *** the Licensed Calcitonin Product, including *** or any failure by Unigene with respect to its supply obligations hereunder; (G) any material breach by Unigene of its obligations under this Agreement;
(H) changes in applicable laws relating to the development or manufacture of a Licensed Calcitonin Product which materially and adversely affect Tarsa’s or its Affiliates’ or Sublicensees’ ability to develop or manufacture the
Licensed Calcitonin Product in accordance with the Development Timeline, or (I) other external factors not in the reasonable control of Tarsa or its Affiliates or Sublicensees. External Factors shall be determined on a country-by-country basis.
Promptly after learning of the occurrence of an External Factor, Tarsa shall notify Unigene in writing of the External Factor, and shall provide Unigene with all information reasonably requested by Unigene regarding such External Factor and with
Tarsa’s plan to overcome such External Factor, which plan shall provide for *** for the Licensed Calcitonin Product, *** as soon as reasonably practicable. The relevant date(s) in the Development Timeline (and any subsequent dates) shall be
extended by mutual agreement of the Parties based upon Tarsa’s reasonable assessment of the period of time required to reach the applicable milestone event in light of the relevant External Factors. 
 (c) Transfer of IND. On the Effective Date, Unigene shall execute and deliver to Tarsa letters addressed to the applicable Regulatory
Authority of each country in which Unigene has filed a Calcitonin IND, a form of which, applicable to the United States, is attached hereto as Schedule 5, pursuant to which Unigene assigns, or seeks permission from such Regulatory Authority
to assign, to Tarsa each such Calcitonin IND (the “IND Assignments”). Subject to Unigene’s receipt of the payment specified in Section 4.1, Tarsa shall have the right to file the IND Assignments with the applicable
Regulatory Authorities or to cause Unigene to file such IND Assignments in those countries where Tarsa is not permitted by such Regulatory Authority to make such filing on Unigene’s behalf. Until such time as the assignment of each Calcitonin
IND becomes effective, Unigene hereby grants to Tarsa a Right of Reference in the Field in the Territory to the data included in all regulatory filings by Unigene related to the Licensed Calcitonin Product to the extent necessary or useful to fully
exercise the rights granted to Tarsa hereunder. Unigene will provide a signed statement to effect this Right of Reference, if requested by Tarsa, in accordance with 21 C.F.R. § 314.50(g)(3) or any foreign counterpart to such regulation, for the
purpose of Tarsa exercising its rights or performing its obligations under this Agreement. Without limiting the foregoing, Unigene agrees to execute, acknowledge and deliver any such further documents and to do such other acts as may be reasonably
necessary or reasonably appropriate in order to carry out the purpose and intent of this Section 3.1(c), at Tarsa’s cost and expense, provided that Unigene shall notify Tarsa of any such costs and expenses that Unigene would expect
to be incurred prior to taking any such acts, and such costs and expenses shall be approved by Tarsa in writing prior to Unigene’s taking such acts, it being understood that if Tarsa refuses to approve such costs and expenses, Unigene shall
have no obligation to take such acts. 
  

 - 22 - 

 (d) Calcitonin API. Unigene shall, upon Tarsa’s written request, use
Commercially Reasonable Efforts to provide to Tarsa reasonable quantities of Calcitonin API from Unigene’s current stock of Calcitonin API, or manufacture for Tarsa reasonable quantities of Calcitonin API, for use in research, development and
clinical studies for Licensed Calcitonin Products, provided that Unigene shall provide to or manufacture for Tarsa the requested Calcitonin API only to the extent that doing so would not violate the terms of the CM Agreement, including any exclusive
purchase obligations thereunder. Any Calcitonin API delivered under this Section 3.1(d) shall, subject to Section 2.3(e), comply in all material respects with Current Good Manufacturing Practices as defined in 21 CFR §
210 et seq., Calcitonin API Specifications as contemplated by Clause 15 of the CM Agreement and applicable law. Unigene shall provide Tarsa with certificates of analysis, certificates of compliance and documentation of storage conditions for any
Calcitonin API supplied to Tarsa under this Section 3.1(d). Tarsa shall reimburse Unigene for its manufacture of Calcitonin API under this Section 3.1(d) at *** Calcitonin API. 
 (e) Data Transfer. Promptly after the Effective Date and subject to Section 2.3 and Section 2.4, Unigene
shall provide Tarsa with a copy of (i) all readily available data and other documentation (including Regulatory Materials) under Unigene’s Control that are necessary to obtain or maintain Regulatory Approval of the Calcitonin Product that
is a Licensed Calcitonin Product and which Unigene is permitted to disclose to Tarsa and (ii) all Assigned Contracts. 
 (f) Assignment of Assigned Contracts. On the Effective Date, Unigene shall execute and deliver to Tarsa an instrument of assignment mutually agreed to by the Parties (the “Assignment Agreement”), pursuant to which
Unigene shall assign, and Tarsa shall accept, subject to the terms and conditions of such Assignment Agreement, all of Unigene’s right, title and interest in, to and under the Assigned Contracts. Unigene shall maintain all Assigned Contracts in
full force and effect until the Effective Time, and Tarsa shall be responsible for amounts required to be paid by Unigene to Third Parties under the Assigned Contracts from the Effective Date until the Effective Time, after which Tarsa shall be
responsible for Assumed Liabilities under and in accordance with the Assignment Agreement. 
 (g) Updates and Reports. In
addition to royalty information reports to be provided by Tarsa pursuant to Section 4.5 hereof, Tarsa shall provide Unigene with written semi-annual reports, summarizing Tarsa’s efforts to conduct *** and commercialization of the Licensed
Products as contemplated hereunder, provided that Tarsa shall not have to provide such reports or updates with respect to the *** during such time that Unigene is solely responsible for developing *** pursuant to services being provided
pursuant to Section 2.7. For the avoidance of doubt, such reports shall at minimum discuss in a reasonably detailed fashion the steps Tarsa has taken in the immediately preceding six (6) months with respect to its obligations under
this ARTICLE III. In addition, Tarsa shall provide Unigene with prompt written notice of the occurrence of the First Commercial Sale of each of the Licensed Products. All such reports and updates shall be considered Confidential Information
of Tarsa, subject to the terms of ARTICLE V hereof. 
  

 - 23 - 

 (h) ***. If Tarsa wishes to have research services performed on its behalf by ***,
pursuant to the ***, dated ***, between Unigene and ***, Tarsa shall notify Unigene thereof and the Parties shall discuss in good faith the terms thereof. Unigene is a party to a ***, dated ***, with ***. As of the Effective Date, there is no
intellectual property licensed from *** under the *** License Agreement that will be Necessary or useful for the development, testing, manufacture, use or sale of any Licensed Calcitonin Product in the Field in the Territory. If Unigene becomes
licensed under the *** License Agreement and Controls any intellectual property that (i) arose before or during the IP Term or for which an application was filed before or during the IP Term and (ii) is Necessary for the development,
testing, manufacture, use or sale of any Licensed Calcitonin Product, then Unigene shall notify Tarsa thereof in writing and, upon Tarsa’s written request, such intellectual property shall be deemed Licensed Calcitonin IP without any further
action by the Parties. 
 (i) ***. Unigene agrees, upon Tarsa’s written request, to use its Commercially Reasonable
Efforts, at Tarsa’s expense, to either (A) *** or other conveyance *** under Section 7.2 of the *** Agreement to enable Tarsa to *** and *** (as such terms are defined under the ***) for the *** or (B) waive a portion of
Unigene’s right of *** under Section 7.2 of the *** to permit Tarsa *** to *** and *** for the ***, as mutually agreed by the Parties. 
 Section 3.2. Product Safety. In the event that either Party receives a complaint from a Regulatory Authority or becomes aware of any adverse event regarding a Licensed Product, including
receipt of any notice from *** or *** if relating to any components that are common to a Licensed Product and any *** or *** product, of any adverse event regarding a Licensed Product, then such Party immediately shall inform the other Party of the
nature of the complaint or such adverse event and the need for resolution. Tarsa shall be solely responsible for the record keeping and timely reporting of all adverse events and other safety related issues relating to the Licensed Products sold by
or on behalf of Tarsa or its Sublicensees. In the event of any market withdrawal or recall of any such Licensed Products at the request of any Regulatory Authority, or if Tarsa reasonably believes such action is otherwise warranted, Tarsa shall be
solely responsible for such market withdrawal or recall of such Licensed Products sold by or on behalf of Tarsa or its Sublicensees. Subject to the provisions of the CM Agreement, Tarsa shall bear all costs and expenses incurred in connection with
such withdrawal or recall (whether or not incurred while this Agreement is in effect), unless and to the extent that such withdrawal or recall is the result of any failure by Unigene to accurately and correctly perform analysis of samples of
Calcitonin API for compliance with the Calcitonin API Specifications pursuant to Section 2.3(b). Upon Tarsa’s written request, Unigene shall reasonably cooperate with Tarsa, at Tarsa’s expense, in performing testing and defect
analysis of any such Licensed Product that is withdrawn or recalled. 
  

 - 24 - 

 Section 3.3. Coordination of Development Activities. Unigene shall consult with
Tarsa prior to undertaking any clinical trials in the Unigene Field, and Tarsa shall consult with Unigene prior to undertaking any clinical trials in the Field, and each Party shall consider the other Party’s comments in good faith;
provided, however, that Sublicensees of a Party shall not be obligated to consult with the other Party regarding clinical trials or otherwise be obligated to the other Party pursuant to this Section 3.3. 
 Section 3.4. Limits on Competing Products. 
 (a) Tarsa agrees that, during the Term, it shall not, whether on its own or with or for a Third Party, research, develop or commercialize in the Territory any *** product, other than the Licensed
Calcitonin Products. Tarsa further agrees that, if Tarsa ***, whether through exercise by Tarsa or its Sublicensees of the licenses granted by Unigene pursuant to Section 2.1(c) or purchase by Tarsa or its Sublicensees of *** through
Unigene pursuant to Section 2.4, then Tarsa shall not, during the Term, whether on its own or with or for a Third Party, research, develop or commercialize in the Territory any product *** using such *** other than the ***. 

(b) Unigene agrees that, during the Term, it shall not, whether on its own or with or for a Third Party, research, develop or
commercialize in the Territory any *** product of any *** or otherwise *** that (i) provides only a *** versus ***, (ii) would obtain *** via any process other than *** of the *** or any foreign counterparts or (iii) *** in each case
for the *** other than (A) in the Unigene Field or (B) *** for any research, development or commercialization by *** of the oral calcitonin product currently in Phase III studies conducted by *** on the Effective Date, or as otherwise
required under the *** License Agreement (as in effect on the Effective Date). 
 ARTICLE IV 
 PAYMENTS AND ROYALTIES. 
 Section 4.1. Reimbursement for Phase III Trials. 
 (a) No later than
*** after the Effective Date, Tarsa will reimburse Unigene for (i) *** documented out-of-pocket Third Party costs directly related to execution of its Phase III oral calcitonin clinical trial, *** (ii) *** incurred by Unigene before the
Effective Date and directly paid by Unigene to *** pursuant to the *** and (iii) *** pursuant to the ***. As of October 15, 2009, the total out-of-pocket costs associated with activities under clause (i) were approximately ***. As of
the Effective Date, the *** under clause (ii) are *** and the *** under clause (iii) are ***. For the avoidance of doubt, Tarsa shall be solely responsible for all costs and expenses incurred by Tarsa or Unigene relating to the execution
of such Phase III clinical trial described in clause (i) after the Effective Date. 
 (b) Without limitation of
Section 2.7, Tarsa will reimburse Unigene for all *** directly related to (i) the conduct of the Phase III oral calcitonin clinical trial, subject to and in accordance with Section 3.1(a) and (ii) filings for
Regulatory Approval made on behalf of Tarsa, subject to and in accordance with Section 3.1(c), in each case that are incurred by Unigene from and after the Effective Date until the Effective Time. Unigene shall obtain Tarsa’s prior
approval for any such Third Party costs that are expected to exceed ***. 
  

 - 25 - 

 Section 4.2. Royalties. In consideration of the grant of the License by Unigene
hereunder, and subject to the other terms of this Agreement, commencing on the date of the First Commercial Sale of a Licensed Product and continuing on a country-by-country basis in the Territory as set forth below, Tarsa shall pay to Unigene the
following royalty amounts: 
 (a) with respect to all countries where at least one (1) Valid Claim of the Licensed
Calcitonin Patent Rights Cover the Licensed Calcitonin Product: 
 (i) for Net Sales of Licensed Calcitonin Product (other than
the ***) equal to or less than *** in the aggregate in any calendar year following the First Commercial Sale date, Tarsa shall pay to Unigene a royalty payment, in immediately available cash, equal to *** of such Net Sales; 
 (ii) for Net Sales of Licensed Calcitonin Product (other than the ***) that are greater than *** in the aggregate in any calendar year
following the First Commercial Sale date, Tarsa shall pay to Unigene a royalty payment, in immediately available cash, equal to *** of such Net Sales; 
 (iii) for Net Sales of the *** Product equal to or less than *** in the aggregate in any calendar year following the First Commercial Sale date, Tarsa shall pay to Unigene a royalty payment, in
immediately available cash, equal to *** of such Net Sales, notwithstanding the provisions set forth in the third paragraph of the definition of “Net Sales” set forth in Section 1.1; 
 (iv) for Net Sales of the *** Product that are greater than *** in the aggregate in any calendar year following the First Commercial Sale
date, Tarsa shall pay to Unigene a royalty payment, in immediately available cash, equal to *** of such Net Sales, notwithstanding the provisions set forth in the third paragraph of the definition of “Net Sales” set forth in
Section 1.1; and 
 For purposes of example, if Net Sales of a Licensed Calcitonin Product (other than a ***
Product) in a calendar year are *** the royalties due and payable to Unigene shall be calculated as *** of the first *** plus *** of the next ***. 
 (b) with respect to all countries where no Valid Claim under the Licensed Calcitonin Patent Rights Covers a particular Licensed Calcitonin Product, Tarsa shall pay to Unigene royalty payments at a rate of
*** of the amounts set forth in Section 4.2(a) above. Royalties under this Section 4.2(b) shall be payable in respect of each country where no Valid Claim under the Licensed Calcitonin Patent Rights Cover the applicable
Licensed Calcitonin Product until the date that is *** years after the First Commercial Sale of such Licensed Calcitonin Product in such country, provided that if, after First Commercial Sale of the applicable Licensed Calcitonin Product in a
country, such Licensed Calcitonin Product is not actively offered for sale in such country for any period of time, then the period of time during which royalties under this Section 4.2(b) are payable shall be extended by the amount of
time during which such Licensed Calcitonin Product was not actively offered for sale in such country. For the avoidance of doubt, without limitation of Section 4.2(a), with respect to each Licensed Calcitonin Product where at least one
(1) Valid Claim of the Licensed Calcitonin Patent Rights has Covered the Licensed Calcitonin Product in a country for *** years or more after the First Commercial Sale of such Licensed Calcitonin Product in such country, and such Licensed
Calcitonin Product was actively offered for sale in such country for at least *** years after such First Commercial Sale, no further payments shall be due under this Section 4.2(b) in such country based on Net Sales of such Licensed
Calcitonin Product; 
  

 - 26 - 

 (c) with respect to all countries where at least one (1) Valid Claim of the Licensed
*** Patent Rights Covers the manufacture of a Licensed *** Product containing *** manufactured by Tarsa or its Affiliates or Sublicensees under the license granted pursuant to Section 2.1(c) (a “Royalty-Bearing Licensed ***
Product”), Tarsa shall pay to Unigene, following First Commercial Sale of such Royalty-Bearing Licensed *** Product, a royalty payment, in immediately available cash, equal to *** of Net Sales of such Royalty-Bearing Licensed *** Product;

 (d) with respect to all countries where no Valid Claim under the Licensed *** Patent Rights Covers the manufacture of a
particular Royalty-Bearing Licensed *** Product, Tarsa shall pay to Unigene royalty payments at the same rate set forth in Section 4.2(c) above. Royalties under this Section 4.2(d) shall be payable in respect of each country
where no Valid Claim under the Licensed *** Patent Rights Covers a particular Royalty-Bearing Licensed *** Product until the date that is *** years after the First Commercial Sale of such Royalty-Bearing Licensed *** Product in such country,
provided that if, after First Commercial Sale of the applicable Royalty-Bearing Licensed *** Product in a country, such Royalty-Bearing Licensed *** Product is not actively offered for sale in such country for any period of time, then the period of
time during which royalties under this Section 4.2(d) are payable shall be extended by the amount of time during which such Royalty-Bearing Licensed *** Product was not actively offered for sale in such country. For the avoidance of
doubt, without limitation of Section 4.2(c), with respect to each Royalty-Bearing Licensed *** Product where at least one (1) Valid Claim of the Licensed *** Patent Rights has Covered the Royalty-Bearing Licensed *** Product in a
country for *** years or more after the First Commercial Sale of such Royalty-Bearing Licensed *** Product in such country, and such Royalty-Bearing Licensed *** Product was actively offered for sale in such country for at least *** years after such
First Commercial Sale, no further payments shall be due under this Section 4.2(d) in such country based on Net Sales of such Royalty-Bearing Licensed *** Product; 
 (e) If Tarsa’s outside patent counsel reasonably determines in good faith that, in order to avoid infringement of any patent not
licensed hereunder, it is necessary to obtain a license from a Third Party in order to make, use, sell, offer for sale, supply, cause to be supplied or import a Licensed Calcitonin Product in a country in the Territory or to manufacture *** under
the license granted to Tarsa by Section 2.1(c), and to pay a royalty or other consideration under such license (including in connection with the settlement of a patent infringement claim), or shall be subject to a final court or other
binding order or ruling or settlement agreement requiring any payments, including the payment of a royalty to a Third Party patent holder in respect of sales of any Licensed Product in a country in the Territory, then, without limiting
Unigene’s obligations under ARTICLE VII, the amount of Tarsa’s royalty payments under Section 4.2 with respect to Net Sales for such Licensed Products in such country shall be reduced by *** of the amount payable by
Tarsa to such Third Party; provided, however, that: 
 (i) in no event will a deduction, or deductions, under
this Section 4.2(e) in the aggregate, reduce any royalty payment made by Tarsa in respect of Net Sales of such Licensed Product pursuant to Section 4.2 by more than *** (the “Royalty Reduction Limit”);

  

 - 27 - 

 (ii) in the event any royalty payment reductions pursuant to the terms of
Section 4.2(b) apply, such Royalty Reduction Limit shall be calculated as *** of such reduced royalty payment amounts. 
 Section 4.3. Milestone Payments. In addition to the royalties payable under Section 4.2, Tarsa shall pay to Unigene, within *** days after the end of the *** in which each of the following milestones are first
achieved: 
 (a) *** when aggregate Net Sales for Licensed Calcitonin Product first exceed ***; and 
 (b) *** when aggregate Net Sales for all *** Products first exceed ***. 
 Tarsa shall notify Unigene of the occurrence of the foregoing milestone events within *** days after the end of the *** in which the
applicable milestone has been achieved. The foregoing milestones shall be triggered by the achievement of the specified event by the applicable Licensed Product whether by Tarsa, its Affiliates and/or its Sublicensees. The foregoing milestone
payment shall be non-refundable and non-creditable. 
 Section 4.4. Payment. All payments to be made by Tarsa
hereunder shall be made in United States Dollars by wire transfer of immediately available funds to such United States bank account as shall be designated by Unigene within *** days of any applicable due date, and shall be computed in United States
dollars at the exchange rate prevailing in each country in the Territory at the close of the last business day of the applicable calendar quarter. The exchange rates used for such conversion shall be those set forth in the Wall Street Journal, New
York edition. Late payments shall bear interest at the rate of *** of the outstanding balance per month as prorated, or the maximum amount permitted by law, whichever is less. 
 Section 4.5. Sales Reports and Royalty Payments. After the First Commercial Sale of a Licensed Product and during the Term,
Tarsa shall furnish to Unigene a written report, with respect to such Licensed Product, within *** days after the end of each calendar quarter (or portion thereof, if this Agreement terminates during a calendar quarter), showing the amount of
royalty due for the immediately preceding calendar quarter (or portion thereof). Royalty payments for each calendar quarter shall be due within *** days after the end of each calendar quarter (or portion thereof, if this Agreement terminates during
a calendar quarter). Each written report shall include a full and accurate accounting of: 
 (a) the gross sales and quantity of
each Licensed Product sold by Tarsa, its Affiliates, and Sublicensees in the preceding calendar quarter; 
  

 - 28 - 

 (b) the calculation of Net Sales from such gross sales, including each deduction; and

 (c) the royalties payable in United States Dollars which shall have accrued hereunder in respect of such Net Sales.

 If no royalty or payment is due for any royalty period hereunder, Tarsa shall so report to Unigene in writing. 
 Section 4.6. Tax Withholding; Restrictions on Payment. All payments hereunder shall be made free and clear of any taxes, duties,
levies, fees or charges, except for withholding taxes (to the extent mandated by applicable law). Tarsa shall make any applicable withholding payments due on behalf of Unigene and shall provide Unigene upon request with such written documentation
regarding any such payment as is available to Tarsa. 
 Section 4.7. Sales Record Audit. Tarsa shall keep, and shall
cause each of its Affiliates, and Sublicensees, if any, to keep, full and accurate books of accounting in accordance with U.S. generally accepted accounting principals, as may be reasonably necessary for the purpose of calculating the royalties
payable to Unigene. Such books of accounting (including those of Tarsa’s Affiliates, and Sublicensees, if any) shall be kept at their principal place of business and, with all necessary supporting data, shall during all reasonable times for the
three (3) years next following the end of the calendar year to which each shall pertain, be open for inspection at reasonable times upon written notice by Unigene and at Unigene’s sole cost (except as provided below), no more than once per
year, by an independent certified public accountant, agent or Unigene employee selected by Unigene, for the purpose of verifying royalty statements for compliance with this Agreement. Such accountant, agent or employee shall have agreed in writing
to maintain all information learned in confidence, except as necessary to disclose to Unigene such compliance or noncompliance by Tarsa. The results of each inspection, if any, shall be binding on both Parties. Unigene shall pay for such
inspections, except that in the event there is any upward adjustment in aggregate royalties payable for the period of such inspection of more than *** of the amount actually paid to Unigene, Tarsa shall pay for the reasonable out-of-pocket Third
Party costs of such audit. 
 ARTICLE V 
 CONFIDENTIAL INFORMATION 
 Section 5.1. Confidentiality
Obligations. Each of Unigene and Tarsa agree that during the Term and for *** thereafter, it shall keep confidential, and shall cause its employees, consultants, Affiliates, agents, subcontractors, and sublicensees to keep confidential, all
Confidential Information of the other Party. Unigene further agrees that neither Unigene nor its Affiliates shall disclose to any Third Party any Confidential Information of Unigene relating to the Licensed Products or the data or results from any
clinical study, the subject of which is a Licensed Product, without first obtaining from such Third Party obligations of confidentiality substantially the same as those set forth in this ARTICLE V, with such changes as may commercially reasonable
under the circumstances, provided that the foregoing shall not be deemed to require Unigene to amend the terms of any of Unigene’s existing agreements with Third Parties, and Unigene may disclose its Confidential Information to such Third
Parties under the terms of such agreements without violating the requirements set forth in this sentence, including under the terms of the VPC Financing Agreement. Neither Unigene nor Tarsa nor any of their employees, consultants, Affiliates,
agents, subcontractors, or sublicensees shall use Confidential Information of the other Party for any purpose whatsoever other than to exercise any rights granted to it or reserved by it hereunder or to carry out its responsibilities hereunder.
Without limiting the foregoing but subject to Section 5.2, Section 5.3 and Section 5.4 below, each Party may disclose information to the extent such disclosure is reasonably necessary to (a) file and
prosecute patent applications and/or maintain patents which are filed or prosecuted in accordance with the provisions of this Agreement, (b) file, prosecute or defend litigation in accordance with the provisions of this Agreement, or
(c) comply with applicable laws, regulations or court orders or the requirements of the U.S. Securities and Exchange Commission (“SEC”) or any nationally recognized securities exchange, quotation system or over-the-counter
market on which such Party has its securities listed or traded; provided, however, that if a Party is required to make any such disclosure of the other Party’s Confidential Information in connection with any of the foregoing, it
shall give reasonable advance notice to the other Party of such disclosure requirement and shall use reasonable efforts to assist such other Party in efforts to secure confidential treatment of such information required to be disclosed.
Notwithstanding anything to the contrary herein, Unigene shall have the right to disclose Tarsa Confidential Information to the Lending Parties solely for use by the Lending Parties and solely to the extent necessary to protect their interests under
the VPC Financing Agreement, provided that (i) the Lending Parties shall agree in writing with Unigene to maintain the confidentiality of such Tarsa Confidential Information on terms substantially the same as those set forth in this ARTICLE V
prior to the delivery of such Tarsa Confidential Information to the Lending Parties, (ii) Tarsa is a third party beneficiary of such written agreement between the Lending Parties and Unigene and (iii) Unigene provides Tarsa with prior
written notice of any such disclosure of Tarsa Confidential Information to the Lending Parties. 
  

 - 29 - 

 Section 5.2. Exclusions. The obligations of confidentiality and non-use imposed
by this ARTICLE V shall not apply to any information, data or materials that a receiving Party can demonstrate by written records or other tangible evidence, (a) as of the date of disclosure is demonstrably known to the receiving Party
or its Affiliates other than by virtue of a prior confidential disclosure to such Party or its Affiliates; (b) as of the date of disclosure is in, or subsequently becomes publicly known, through no fault or omission of the receiving Party or
its Affiliates; (c) is obtained from a Third Party having a lawful right to make such disclosure free from any obligation of confidentiality to the disclosing Party; or (d) is independently developed by or for the receiving Party or its
Affiliates without reference to or reliance upon any Confidential Information of the disclosing Party. 
 Section 5.3.
Limited Disclosure and Use. Unigene and Tarsa each agree that any disclosure of the other Party’s Confidential Information to any of its employees, consultants, Affiliates, agents, subcontractors, or sublicensees shall be made only if
and to the extent necessary to carry out its rights and responsibilities under this Agreement, shall be limited to the maximum extent possible consistent with such rights and responsibilities, and shall only be made if such Persons are bound by
written confidentiality obligations to maintain the confidentiality thereof and not to use such Confidential Information except as expressly permitted by this Agreement. Unigene and Tarsa each further agree not to disclose or transfer the other
Party’s Confidential Information to any Third Parties under any circumstance without the prior written approval from the other Party, except as otherwise required by law, and except as otherwise expressly permitted by this Agreement. Each Party
shall take such action, and shall cause its employees, consultants, Affiliates, agents, subcontractors, and sublicensees to take such action, to preserve the confidentiality of each other Party’s Confidential Information as it would customarily
take to preserve the confidentiality of its own Confidential Information. Each Party, upon the termination of this Agreement, shall return all the Confidential Information disclosed or transferred to it by the other Party pursuant to this Agreement,
including all copies and extracts of documents and all manifestations of Confidential Information in any form; provided, however, that a Party may retain (a) any Confidential Information of the other Party relating to any license
which expressly survives such termination provided such Confidential Information shall remain subject to obligations of confidentiality, and (b) one (1) copy of all other Confidential Information in inactive archives solely for the purpose
of maintaining a record of information and materials deemed to be Confidential Information hereunder. 
  

 - 30 - 

 Section 5.4. Publicity. Neither Party may publicly disclose the existence or
terms or any other matter of fact regarding this Agreement without the prior written consent of the other Party; provided, however, that either Party may make such a disclosure (a) to the extent required to comply with applicable
laws, regulations or court orders or the requirements of the SEC or any nationally recognized securities exchange, quotation system or over-the-counter market on which such Party has its securities listed or traded, or (b) to any actual or
prospective sublicensees, investors, lenders, other financing sources, acquirors, or companies being acquired by such Party who are obligated in writing to keep such information confidential on terms as protective as terms of this ARTICLE V.
The Party desiring to make any such disclosure under clause (a) above shall inform the other Party of the proposed announcement or disclosure in reasonably sufficient time prior to public release, which shall be at least three (3) business
days, and shall provide the other Party with a written copy thereof. Each Party agrees that it shall cooperate fully with the other with respect to all disclosures regarding this Agreement to the SEC and any other governmental or regulatory
agencies, including requests for confidential treatment of proprietary information of either Party included in such disclosure. 
 Section 5.5. Use of Name; Press Release. Neither Party shall employ or use the name of the other Party in any promotional materials or advertising without the prior express written permission of the other Party. After execution
of this Agreement by the Parties, each of the Parties shall have the right to issue a press release, provided that the other Party is provided with an opportunity to review the press release at least three (3) days in advance of its
proposed release date, and such other Party shall have the right to object to and prohibit the disclosure of any of its Confidential Information included in such press release. 
 ARTICLE VI 
 INTELLECTUAL PROPERTY 

Section 6.1. Licensed IP. As between the Parties, Unigene shall retain sole ownership of all rights, title and interest in
and to the Licensed IP and *** IP. 
 Section 6.2. Improvements. 
  

 - 31 - 

 (a) Unigene shall exclusively own all Collaboration Improvements and Unigene Sole
Improvements. Tarsa shall exclusively own all Tarsa Sole Improvements. Each Party shall own an equal, undivided interest in and to the Joint Improvements, and each Party shall be free to exploit any Joint Improvement throughout the world without
restriction, without the consent of the other Party and without any payment of compensation or duty of accounting to the other. 
 (b) Each Party promptly shall notify the other Party of any Improvements made by it. Each Party hereby assigns to the other Party such of its rights, title and interest in the Improvements and any intellectual property rights therein or
related thereto to the extent necessary to give effect to the provisions of this Section 6.2, without the need of any additional consideration or any further action. If a separate express assignment of rights from one Party to the other
is required in order to give full force and effect to this Section 6.2, the assigning Party agrees, at the other Party’s expense, to execute any instrument necessary to accomplish the intent of the foregoing. Each Party shall ensure
that any Person involved in the development of any Improvement has assigned its rights in such Improvement to such Party so that such Party can make the assignment required under this Section 6.2. 
 Section 6.3. Inventorship. Inventorship and authorship of inventions and other intellectual property rights conceived, reduced
to practice and/or authored in connection with this Agreement shall be determined in accordance with the laws of the United States. 
 ARTICLE VII 
 PROVISIONS CONCERNING THE FILING, PROSECUTION 
 AND MAINTENANCE OF LICENSED PATENT RIGHTS 
 Section 7.1. Cooperation. The Parties agrees to cooperate with all reasonable requests of the other Party in the filing and prosecution of the Licensed Patent Rights and any Patent Rights
relating to the *** IP or Improvements. 
 Section 7.2. Patent Filing, Prosecution and Maintenance. 
 (a) Subject to the other terms of this ARTICLE VII, Tarsa, at its expense, shall have the sole right but not the obligation to
prepare, file, prosecute and maintain, throughout the world, any Patent Rights relating to the Tarsa Sole Improvements, including seeking any extensions thereto and supplementary protection certificates therefor. Tarsa shall have the first right but
not the obligation to file or continue prosecution or maintenance of any application for any such Patent Right relating to any Tarsa Sole Improvement using patent counsel selected by Tarsa and acceptable to Unigene. Before filing an application for
any such Patent Right, Tarsa shall give Unigene a reasonable opportunity to review and comment upon the text of the application. Tarsa shall consult with Unigene with respect to any such application, shall not unreasonably refuse to address or
incorporate or reflect any of Unigene’s comments with respect to such application to the extent relevant to the rights licensed to Unigene hereunder, and shall supply Unigene with a copy of each such application as filed, together with notice
of its filing date and serial number. Tarsa shall also keep Unigene advised of the status of prosecution of all such patent applications included within the Patent Rights relating to Tarsa Sole Improvements and shall address or incorporate
Unigene’s reasonable comments with respect thereto if relevant to the rights licensed to Unigene hereunder, and provide Unigene with a reasonable opportunity to comment, if relevant to the rights licensed to Unigene hereunder, on all material
correspondence received from and all material submissions to be made to any government patent office or authority with respect to any such patent application or patent. In addition, if Tarsa elects not to file in any country in the world a patent
application on Tarsa Sole Improvements, or to cease the prosecution or maintenance of such Patent Rights related to Tarsa Sole Improvements in any country in the world, Tarsa shall provide Unigene with prompt written notice upon the decision to not
file or continue the prosecution of such patent application or maintenance of such patent in sufficient time to allow Unigene to file, continue prosecution of such application or maintain such patent in a timely manner. Under no circumstances will
this written notice occur less than thirty (30) days prior to such required action for the filing, maintenance or prosecution of such patents. In such event, Tarsa shall permit Unigene, at Unigene’s reasonable discretion, to file or
continue prosecution or maintenance of such Patent Rights related to the Tarsa Sole Improvements in the applicable country at Unigene’s own expense, provided, however, that any such action does not violate the terms of any
judgment, settlement, compromise or other resolution binding upon Tarsa. 
  

 - 32 - 

 (b) Subject to the other terms of this ARTICLE VII, Unigene, at its expense, shall
have the sole right but not the obligation to prepare, file, prosecute and maintain, throughout the world, the Licensed Patent Rights (including the Patent Rights relating to any Collaboration Improvements and Unigene Sole Improvements) and the ***
IP (collectively, the “Unigene-Controlled Patent Rights”), including seeking any extensions thereto and supplementary protection certificates therefor. Before filing an application for any such Patent Right, Unigene shall give Tarsa
a reasonable opportunity to review and comment upon the text of the application. Unigene shall consult with Tarsa with respect to any such application, shall not unreasonably refuse to address or incorporate or reflect any of Tarsa’s comments
with respect to such application to the extent relevant to the rights licensed to Tarsa hereunder, and shall supply Tarsa with a copy of each such application as filed, together with notice of its filing date and serial number. Unigene shall also
keep Tarsa advised of the status of prosecution of all such patent applications included within the Unigene-Controlled Patent Rights and shall address or incorporate Tarsa’s reasonable comments with respect thereto if relevant to the rights
licensed to Tarsa hereunder, and provide Tarsa with a reasonable opportunity to comment on all material correspondence received from and all material submissions to be made to any government patent office or authority with respect to any such patent
application or patent. Subject to *** rights under the *** License Agreement and *** rights under the *** Agreement, if Unigene elects not to file in any country in the Territory a patent application on a Unigene-Controlled Patent Right, or to cease
the prosecution or maintenance of such Unigene-Controlled Patent Rights, Unigene shall provide Tarsa with prompt written notice upon the decision to not file or continue the prosecution of such patent application or maintenance of such patent in
sufficient time to allow Tarsa to file, continue prosecution of such application or maintain such patent in a timely manner. Under no circumstances will this written notice occur less than thirty (30) days prior to such required action for the
filing, maintenance or prosecution of such patents. In such event, and subject to *** rights under the *** License Agreement and *** rights under the *** Agreement, Unigene shall permit Tarsa, at Tarsa’s reasonable discretion, to file or
continue prosecution or maintenance of such Unigene-Controlled Patent Rights in the applicable country at Tarsa’s own expense, provided, however, that any such action does not violate the terms of any judgment, settlement, compromise or other
resolution binding upon Unigene. 
  

 - 33 - 

 (c) In the case of Joint Improvements, the Parties shall decide whether or not to secure
patent protection and which Party shall bear the primary responsibility for preparing, filing and prosecuting the patent applications resulting therefrom. Patent-related expenses for Joint Improvements are to be shared equally by the Parties. If the
Parties cannot agree which Party shall bear the primary responsibility for preparing, filing, and prosecuting patent applications resulting from a Joint Improvement, then counsel mutually agreeable to the Parties shall prepare, file and prosecute
the patent applications and the Parties shall equally share the expenses related thereto. Each Party shall promptly render all necessary assistance reasonably requested by the other Party in applying for and prosecuting the patent applications.
Neither Party shall file any patent application on Joint Improvements which shall lead to the disclosure of the other Party’s Confidential Information, unless the other Party has first agreed in writing to the filing. If a Party responsible for
the prosecution or maintenance of a patent or patent application directed to a Joint Improvement elects not to continue prosecution or maintenance of such patent or patent application, the Party will give the other Party notice of such election
within a reasonable period prior to allowing such patent or patent application to lapse or become unenforceable, and the other Party will have the right to continue prosecution or maintenance of such patent or patent application. If a Party (the
“Relinquishing Party”) declines to pay its share of patent-related expenses for any patent application or patent directed to a Joint Improvement, the other Party may assume payment of the Relinquishing Party’s share of the
patent-related expenses, and the Relinquishing Party will assign title to such patent application or patent to Party assuming payment. 
 Section 7.3. Notice of Infringement. If, during the Term, either Party learns of any actual, alleged or threatened infringement by a Third Party of any Unigene-Controlled Patent Rights or Patent Rights relating to any
Improvement, such Party shall promptly notify the other Party and shall provide such other Party with available evidence of such infringement. 
 Section 7.4. Infringement of Unigene-Controlled Patent Rights, Improvements and Unigene Patent Rights. 
 (a) Where not precluded by agreements with Third Parties entered into prior to the Effective Date, including the *** License Agreement and *** Agreement as set forth in Section 2.3 and
Section 2.4, respectively, Tarsa shall have the first right (but not the obligation), at its own cost and expense and with legal counsel of its own choice, to bring suit (or take other appropriate legal action) against any actual,
alleged or threatened infringement of the (i) Unigene-Controlled Patent Rights (excluding the *** IP) and Patent Rights relating to Joint Improvements, each in the Field in the Territory and to the extent relevant to the Licensed Products and
(ii) the Patent Rights relating to the Tarsa Sole Improvements. Unigene shall have the right, at its own cost and expense, to be represented in any such action, to the extent involving the Unigene-Controlled Patent Rights or Patent Rights
relating to Joint Improvements, brought by Tarsa by counsel of Unigene’s own choice; provided, however, that under no circumstances shall the foregoing affect the right of Tarsa to control the suit as described in the first sentence of this
Section 7.4. 
  

 - 34 - 

 (b) Where Tarsa is precluded by agreements with Third Parties entered into prior to the
Effective Date from having the first right to bring suit for infringement of the Unigene-Controlled Patent Rights in the Field in the Territory and to the extent relevant to the Licensed Products, Unigene, at Tarsa’s direction and expense,
shall, to the extent permitted by any such agreements, bring suit (or take other appropriate legal action) against any actual, alleged or threatened infringement of such patents (excluding the *** IP). Any such suit or legal action that Tarsa has
required Unigene to file shall be directed and controlled by Tarsa through counsel of its own choice that is reasonably acceptable to Unigene, provided such suit or legal action shall be conducted at Tarsa’s sole expense, including payment of
all attorney and expert witness fees. Tarsa shall reimburse Unigene for all of its out-of-pocket Third Party costs and expenses incurred in any suit or action required by Tarsa to be filed under this Section 7.4(b), and if Tarsa requires
any Unigene personnel to expend time in connection with any such suit or action, Tarsa shall reimburse Unigene for such personnel at the FTE Rate. 
 (c) Where Unigene is precluded by the *** License Agreement from granting to Tarsa the first right to bring suit for infringement of the Unigene Patent Rights in the Field within the Territory to the
extent relevant to the Licensed Products, Unigene, at Tarsa’s direction and expense, shall bring suit (or take other appropriate legal action) against any actual, alleged or threatened infringement of such patents to the extent permitted by the
*** License Agreement. Any such suit or legal action that Tarsa has required Unigene to file shall be directed and controlled by Tarsa through counsel of its own choice that is reasonably acceptable to Unigene, provided that such suit or legal
action shall be conducted at Tarsa’s sole expense, including payment of all attorney and expert witness fees. Tarsa shall reimburse Unigene for all of its out-of-pocket Third Party costs and expenses incurred in any suit or action required by
Tarsa to be filed under this Section 7.4(c), and if Tarsa requires any Unigene personnel to expend time in connection with any such suit or action, Tarsa shall reimburse Unigene for such personnel at the FTE Rate. 
 (d) Notwithstanding Section 7.4(b) and Section 7.4(c), Unigene shall not be required to bring any suit or legal
action if doing so reasonably could be expected to result in, as determined by the opinion of Unigene’s outside counsel, an infringement claim against Unigene by the Third Party or its affiliates against which Tarsa wishes to bring such suit or
legal action. Each Party shall bear its own costs and expenses in connection with this Section 7.4(d). 
 (e) If
Tarsa does not, on its own initiative, file any suit or other legal action against any such infringement or direct Unigene to do so to the extent permitted by this Agreement within *** days after the earliest of notice under Section 7.3,
then Unigene shall have the right to bring suit or take other appropriate legal action against such actual, alleged or threatened infringement with respect to the Unigene-Controlled Patent Rights, in Unigene’s name, upon written notice
delivered to Tarsa within *** days of the expiration of such *** day period. 
 (f) The Parties shall not settle, compromise or
otherwise resolve any suit or legal action addressed by this Section 7.4, nor make any admissions, filings, statements or other disclosures in any such suit or legal action, that would restrict, waive or otherwise encumber or impair the
rights licensed to the applicable Party hereunder with respect to the Unigene-Controlled Patent Rights or Patent Rights relating to Joint Improvements, or subject the other Party to any liability or obligations in connection therewith, without the
prior written consent of that affected Party. 
  

 - 35 - 

 (g) Any damages, monetary awards or other amounts recovered, whether by judgment or
settlement, pursuant to any suit or other legal action taken under this Section 7.4, shall be applied as follows: 
 (i) first, to reimburse the Parties for their respective costs and expenses (including reasonable attorneys’ fees and costs) incurred in prosecuting such enforcement action; and 
 (ii) any amounts remaining shall be allocated as follows: (A) if Tarsa is the Party bringing or taking, or requiring that Unigene
bring or take, such suit or other legal action pursuant to Section 7.4(b) or (c), all such amounts shall be retained by Tarsa, subject to such amounts being treated as Net Sales for which royalties shall be due to Unigene pursuant to
Section 4.2 and (B) if Unigene is the Party bringing such suit or taking such other legal action, all such amounts shall be retained by Unigene. 
 (h) Notwithstanding the foregoing, Tarsa acknowledges and agrees that (i) *** may have the right to join in any suit or other legal action brought by Unigene that is covered by this
Section 7.4 and to share in any recoveries obtained in connection therewith in accordance with the terms and conditions of the *** License Agreement, and (ii) *** may have the initial right to bring a suit or other legal action that
is covered by this Section 7.4, and as a result Tarsa’s rights under this Section 7.4 may be circumscribed if *** or *** exercise their respective rights with respect to any such suit or other legal action. In addition,
Tarsa acknowledges that Unigene does not have the initial right to enforce the *** Patents and that Tarsa’s rights under this Section 7.4 shall be limited to the right to require Unigene to enforce such *** Patents as set forth in
Section 7.4(b) if and when Unigene shall obtain such enforcement rights. 
 (i) If a Party brings any such suit or
legal action hereunder, the other Party agrees to be joined as Party plaintiff if necessary to prosecute such suit or legal action, and to give the Party bringing such action or proceeding reasonable assistance and authority to file and prosecute
the suit; provided, however, that neither Party shall be required to transfer any right, title or interest in or to any property to the other Party or any Third Party to confer standing on a Party hereunder. 
 ARTICLE VIII 
 REPRESENTATIONS, WARRANTIES AND COVENANTS 
 Section 8.1. Unigene. Unigene represents and warrants
and covenants to Tarsa that: 
 (a) The execution and delivery of this Agreement and the performance of the transactions
contemplated hereby have been duly authorized by all appropriate Unigene corporate action; 
  

 - 36 - 

 (b) This Agreement is a legal and valid obligation binding upon Unigene and enforceable in
accordance with its terms, and, except as otherwise set forth herein, the execution, delivery and performance of this Agreement by Unigene does not conflict with any agreement, instrument or understanding to which Unigene is a Party or by which it
is bound; 
 (c) Subject to Section 2.3 and Section 2.4, Unigene Controls the Licensed Patent Rights
existing as of the Effective Date. Unigene is entitled to grant the licenses specified herein. The Licensed Patent Rights existing as of the Effective Date constitute all of the Patent Rights Controlled by Unigene as of the Effective Date that are
Necessary to develop, manufacture, sell and otherwise commercialize the Calcitonin Product that is a Licensed Calcitonin Product as of the Effective Date. Except for the *** License Agreement, CM Agreement and *** Agreement, and except for the
security interests granted by Unigene to (i) Victory Park Management LLC, and other lenders pursuant to the Pledge and Security Agreement, dated September 30, 2008, and related financing documents and (ii) JayNJean Levy Family Limited
Partnership, Unigene has not previously assigned, transferred, conveyed or otherwise encumbered its right, title and interest in the Licensed Patent Rights and Licensed Know-How in the Field within the Territory with respect to the Licensed
Products, and shall not do so during the Term; 
 (d) To Unigene’s Knowledge, there is no actual or threatened infringement
of the Licensed Patent Rights or Unigene Patent Rights in the Field by any Third Party; 
 (e) To Unigene’s Knowledge, the
Licensed Patent Rights and Unigene Patent Rights existing as of the Effective Date are subsisting and are not invalid or unenforceable, in whole or in part. As of the Effective Date, there are no claims, judgments or settlements against, or amounts
with respect thereto owed by, Unigene or any of its Affiliates relating to the Licensed Patent Rights or Unigene Patent Rights. As of the Effective Date, no claim or litigation has been brought against Unigene or to Unigene’s Knowledge against
any Third Party, or to Unigene’s Knowledge threatened by any Third Party, and to Unigene’s Knowledge there is no reasonable basis for a claim, alleging that (i) the Licensed Patent Rights or Unigene Patent Rights are invalid or
unenforceable or (ii) the Licensed Patent Rights or Unigene Patent Rights or the licensing or exploiting of such Patent Rights violates, infringes or otherwise conflicts or interferes with any intellectual property or proprietary right of any
Third Party; 
 (f) As of the Effective Date, there are no claims, judgments or settlements against or owed by Unigene or its
Affiliates or, to Unigene’s Knowledge, pending or threatened claims or litigations against Unigene or its Affiliates, relating to the Licensed IP that are reasonably expected to impact activities under this Agreement; 
 (g) Exhibit C sets forth a true and complete copy of each of the *** License Agreement and CM Agreement that is in full force and
effect as of the Effective Date; 
 (h) To Unigene’s Knowledge, neither ***, Sandoz, *** nor any Assigned Contract Party,
on the one hand, nor Unigene, on the other hand, is in default with respect to a material obligation under, and neither such party has claimed nor has reasonable grounds upon which to claim that the other party is in default with respect to a
material obligation under, the *** License Agreement, CM Agreement, *** Agreement or any Assigned Contract; 
  

 - 37 - 

 (i) Except as set forth in Schedule 6, the assignment of the Assigned Contracts as
contemplated herein will not, with or without the giving of notice or the lapse of time or both, violate, be in conflict with, constitute a default under, permit the termination of, cause the acceleration of the maturity of any debt or obligation of
Unigene under, require the consent of any Assigned Contract Party, constitute a breach of, create a Liability or loss of a benefit under or result in the creation or imposition of any Lien upon any of the Assigned Contracts; 
 (j) Unigene has not waived or allowed to lapse any of its rights under the CM Agreement with respect to material breaches thereof of which
it had knowledge, and no such rights have lapsed or otherwise expired or been terminated; 
 (k) As of the Effective Date,
Unigene has prepared, maintained and retained all Regulatory Materials required to be maintained or reported pursuant to and in accordance with cGCP and cGLP, to the extent required, and applicable laws, and the Regulatory Materials do not contain
any materially false and misleading statements; 
 (l) As of the Effective Date, Unigene has conducted, and to Unigene’s
Knowledge its contractors and consultants have conducted, any and all clinical studies related to the Licensed Products in accordance with cGCP and cGLP, to the extent required, and applicable laws; 
 (m) To Unigene’s Knowledge, Unigene has obtained from its employees and Third Parties involved, for or on behalf of Unigene, in the
development or manufacture of the Licensed Product, rights to information (other than a Right of Reference from ***) that are necessary to develop, test, manufacture, use and sell the Licensed Products and that permit Unigene to grant to Tarsa the
licenses and other rights granted to Tarsa hereunder; 
 (n) Unigene has not been debarred and is not subject to debarment and
will not knowingly use in any capacity, in connection with Unigene’s obligations under this Agreement, any Person who has been debarred pursuant to Section 306 of the FD&C Act, or who is the subject of a conviction described in such
section; 
 (o) The Calcitonin API being supplied to Unigene by Sandoz as of the Effective Date is the Calcitonin API used by
Unigene in the Calcitonin Product that is a Licensed Calcitonin Product as of the Effective Date; 
 (p) Schedule 1 sets
forth a list of each Assigned Contract. Each Assigned Contract is in full force and effect as of the Effective Date, and true and complete copies of each such agreement have been provided to Tarsa; 
 (q) The Licensed IP and the Assigned Contracts, together with Tarsa’s rights under this Agreement, include all Patent Rights,
Technology and Third Party agreements (other than those listed on Schedule 1, Part II) of Unigene as of the Effective Date that are Necessary for formulating, manufacturing, packaging, labeling and storing of the Calcitonin Product that is a
Licensed Calcitonin Product in the Territory as such Licensed Calcitonin Product is formulated, manufactured, packaged, labeled and stored by Unigene in the Field and in the Territory as of the Effective Date; and 
  

 - 38 - 

 (r) Unigene has not ceased the prosecution or maintenance of any domestic or foreign patents
or patent applications included in the Licensed Patent Rights. 
 Section 8.2. Tarsa. Tarsa represents, warrants and
covenants to Unigene that: 
 (a) The execution and delivery of this Agreement and the performance of the transactions
contemplated hereby have been duly authorized by all appropriate Tarsa corporate action; 
 (b) This Agreement is a legal and
valid obligation binding upon Tarsa and enforceable in accordance with its terms, and the execution, delivery and performance of this Agreement by Tarsa does not conflict with any agreement, instrument or understanding to which Tarsa is a Party of
or by which it is bound; 
 (c) With respect to any obligations of Tarsa, including development and commercialization activities
of Tarsa hereunder, Tarsa shall comply in all respects with all applicable laws, including by way of example and not limitation, all regulatory requirements in the countries in which Tarsa files for Regulatory Approval for a Licensed Products,
including maintaining all appropriate Regulatory Approvals for Licensed Products for any jurisdiction within the Territory in which Tarsa is marketing or distributing the Licensed Products 
 (d) Neither Tarsa nor any of its principals, executives, employees or investors has been debarred or is subject to debarment, and Tarsa will
not knowingly use in any capacity, in connection with Tarsa’s rights or obligations under this Agreement, any Person who has been debarred pursuant to Section 306 of the FD&C Act, or who is the subject of a conviction described in such
section; and 
 (e) Tarsa is not aware of any Third Party patent, patent application or other intellectual property rights that
as of the Effective Date would be infringed by making, using or selling the Licensed Products. 
 Section 8.3. No
Warranties. Except as expressly set forth in this Agreement, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTIES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, WRITTEN OR ORAL, AND EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, ALL SUCH
WARRANTIES ARE HEREBY DISCLAIMED, INCLUDING WARRANTIES ARISING BY COURSE OF DEALING, PERFORMANCE, CUSTOM OR USAGE IN THE TRADE, AND IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. 
 Section 8.4. Indemnification. 
 (a) Tarsa Indemnity. Subject to Section 8.4(a), Tarsa shall indemnify, defend and hold harmless Unigene, its Affiliates and their respective directors, officers, employees,
stockholders, agents, licensors, suppliers and manufacturers and their respective successors, heirs and assigns (the “Unigene Indemnitees”) from and against any liability, damage, loss or expense (including reasonable
attorneys’ fees and expenses of litigation) incurred by or imposed upon such Unigene Indemnitees, or any of them, in connection with any Third Party claims, suits, actions, demands or judgments, including product liability matters, to the
extent arising, (i) as a consequence of a material breach by Tarsa of its representations, warranties, covenants or agreements hereunder, (ii) the conduct by or on behalf of Tarsa of clinical trials and development and commercialization
activities relating to the Licensed Products, (iii) out of the development, sale or use by any Person of any Licensed Products sold by or on behalf of Tarsa or any of its Affiliates or Sublicensees under this Agreement or (iv) from an
Assumed Liability (as defined in the Assignment Agreement) under an Assigned Contract from and after the Effective Date, except in each case to the extent caused by the gross negligence, willful misconduct or fraud of Unigene. 
  

 - 39 - 

 (b) Unigene Indemnity. Subject to Section 8.4(a) above, Unigene shall
indemnify, defend and hold harmless Tarsa, its Affiliates and their respective directors, officers, employees, and agents, and their respective successors, heirs and assigns (the “Tarsa Indemnitees”), from and against any
liability, damage, loss or expense (including reasonable attorneys’ fees and expenses of litigation) incurred by or imposed upon such Tarsa Indemnitees, or any of them, in connection with any Third Party claims, suits, actions, demands or
judgments, arising as a result of a material breach by Unigene of its representations, warranties, covenants or agreements hereunder, except to the extent caused by the gross negligence, willful misconduct or fraud of Tarsa. 
 (c) Indemnification Procedures. In the event that any Indemnitee is seeking indemnification under this Section 8.4 from a
Party (the “Indemnifying Party”), the other Party shall notify the Indemnifying Party of such claim with respect to such Indemnitee as soon as reasonably practicable after the Indemnitee receives notice of the claim, and the Party
(on behalf of itself and such Indemnitee) shall permit the Indemnifying Party to assume direction and control of the defense of the claim (including the right to settle the claim solely for monetary consideration) and shall cooperate as requested
(at the expense of the Indemnifying Party) in the defense of the claim; it being understood and agreed that the right to assume the direction and control of such litigation shall be conditioned upon the ongoing existence of each of the following:
(1) the Indemnifying Party expressly agrees in writing to the Indemnified Party without a reservation of rights that, as between the Parties, the Indemnifying Party shall be solely obligated to fully satisfy and discharge the claim
notwithstanding any limitation with respect to indemnification included in this Agreement; (2) such claim is solely for monetary damage, and (3) such claim shall not involve a criminal matter or be a claim being brought by a governmental
authority. The indemnification obligations under this Section 8.4 shall not apply to any harm suffered as a direct result of any delay in notice to the Indemnifying Party hereunder or to amounts paid in settlement of any claim, demand,
action or other proceeding if such settlement is effected without the consent of the Indemnifying Party, which consent shall not be withheld or delayed unreasonably. The Indemnitee, its employees and agents, shall reasonably cooperate with the
Indemnifying Party and its legal representatives in the investigation of any claim, demand, action or other proceeding covered by this Section 8.4. 
 Section 8.5. LIMITATION OF LIABILITY. 
 (a) NEITHER PARTY SHALL BE
LIABLE TO THE OTHER, OR TO ANY THIRD PARTY CLAIMING THROUGH OR UNDER THE OTHER PARTY, FOR ANY LOST PROFITS OR FOR ANY INDIRECT, EXEMPLARY, SPECIAL, CONSEQUENTIAL OR INCIDENTAL DAMAGES OF ANY KIND ARISING OUT OF THIS AGREEMENT, EVEN IF IT HAS BEEN
ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, EXCEPT WITH RESPECT TO A BREACH OF EITHER PARTY’S OBLIGATIONS WITH RESPECT TO ARTICLE V, A PARTY’S INDEMNIFICATION OBLIGATIONS UNDER SECTION 8.4, A PARTY’S INFRINGEMENT OR
MISAPPROPRIATION OF THE INTELLECTUAL PROPERTY RIGHTS OF THE OTHER PARTY, OR A PARTY’S GROSS NEGLIGENCE OR FRAUD. 
  

 - 40 - 

 (b) THE LIMITATIONS OF LIABILITY CONTAINED IN THIS AGREEMENT ARE A FUNDAMENTAL PART OF THE
BASIS OF EACH PARTY’S BARGAIN HEREUNDER, AND NEITHER PARTY WOULD ENTER INTO THIS AGREEMENT ABSENT SUCH LIMITATION OF LIABILITY. 
 Section 8.6. Insurance. Tarsa agrees that during the Term and for *** thereafter it shall keep and maintain the following insurance with reputable carriers reasonably satisfactory to Unigene: comprehensive public liability,
including products liability coverage, with limits of (a) before receipt of Regulatory Approval for any Licensed Product, not less than *** Dollars *** per incident and (b) after receipt of Regulatory Approval for any Licensed Product, not
less than *** Dollars *** per incident or any such greater amount determined by the board of directors of Tarsa, naming Unigene as an additional insured from the Effective Date forward with respect to Tarsa’s performance hereof. Tarsa agrees to
provide Unigene certificates evidencing such coverage within *** after the Effective Date and at least annually thereafter. Such insurance certificates shall state that such insurance shall not be canceled or materially altered except upon written
notice to Unigene. 
 ARTICLE IX 
 TERM AND TERMINATION 
 Section 9.1. Term. The term of this
Agreement (“Term”) shall commence on the Effective Date and shall continue on a country-by-country and Licensed Product-by-Licensed Product basis until no royalties are owed with respect to Net Sales of such Licensed Product in such
country. Following the termination of this Agreement pursuant to the immediately preceding sentence, except as otherwise provided in this ARTICLE IX, the licenses granted hereunder to Tarsa with respect to such Licensed Product in such country shall
become fully-paid and perpetual. 
 Section 9.2. Termination by Unigene. 
 (a) Insolvency. Unigene shall have the right to terminate this Agreement, at Unigene’ sole discretion, on written notice to
Tarsa upon the filing by Tarsa in any court or agency pursuant to any statute or regulation of the United States or any other jurisdiction a petition in bankruptcy or insolvency or for reorganization or similar arrangement for the benefit of
creditors or for the appointment of a receiver or trustee of Tarsa or its assets, or if Tarsa is served with an involuntary petition against it in any insolvency proceeding, upon the *** day after such service if such involuntary petition has not
previously been stayed or dismissed, or upon the making by Tarsa of an assignment of substantially all of its assets for the benefit of its creditors. 
  

 - 41 - 

 (b) Material Breach. Unigene shall have the right to terminate this Agreement, on a
Licensed Product-by-Licensed Product basis, at Unigene’s sole discretion, upon delivery of written notice to Tarsa, in the event of any material breach by Tarsa of any terms and conditions of this Agreement applicable to such Licensed Product,
if such breach has not been cured within (i) *** days with respect to a material breach of Section 3.1(b) hereof, (ii) *** days with respect to a material breach involving the failure to make a payment when due or
(iii) *** days, with respect to any other material breach of this Agreement, after written notice thereof is given by Unigene to Tarsa specifying the nature of the alleged breach, provided that, in the event of a material breach of
Section 3.1(b) hereof, if such breach has not been cured within such ***-day period, but Tarsa has presented a reasonable plan to cure such breach that is reasonably satisfactory to Unigene and has commenced and continued to use
Commercially Reasonable Efforts to cure such breach in accordance with such plan within such ***-day period, then Unigene shall not have the right to terminate this Agreement with respect to the applicable Licensed Product pursuant to this
Section 9.2(b) as a result of such material breach unless Tarsa fails at any time to continue to use Commercially Reasonable Efforts to cure such breach in accordance with such plan, in which case Unigene shall have the right to
terminate this Agreement on *** days’ prior written notice, which notice shall be effective at the end of such *** day period unless Tarsa has recommenced such Commercially Reasonable Efforts. 
 (c) Failure to Commence Dosing. 
 (i) Termination Right of Unigene. If dosing of the *** in a Phase III clinical trial for a Licensed Calcitonin Product has not commenced within *** days of the Effective Date, and such failure to
commence dosing is directly attributable to an act, or omission of an act that would have been commercially reasonable for Tarsa to take, Unigene shall have the right to terminate this Agreement with respect to all Licensed Calcitonin Products if
such act or omission is not cured by Tarsa within *** days after Unigene submits to Tarsa written notice of such failure. Notwithstanding the foregoing, Unigene’s right to terminate this Agreement pursuant to this Section 9.2(c)(i)
shall not apply in the event Tarsa fails to commence dosing due to any External Factors. 
 (ii) Certain Notifications.
In the event Tarsa believes that dosing of the first patient in a Phase III clinical trial for a Licensed Calcitonin Product will not commence, for any reason, within *** days of the Effective Date, Tarsa shall promptly notify Unigene of such
belief; provided, however, that any such notification shall not be deemed to be an admission by Tarsa that Unigene has a right to terminate this Agreement pursuant to Section 9.2(c)(i) above. 
 (d) Termination of Activities. If Tarsa ceases all of its development and commercialization activities pertaining to a Licensed
Calcitonin Product for a period of *** days or longer, then Unigene shall have the right to terminate this Agreement with respect to such Licensed Calcitonin Product if such cessation continues *** days after Unigene submits to Tarsa written notice
of such cessation. 
  

 - 42 - 

 Section 9.3. Termination by Tarsa. 
 (a) Insolvency. Tarsa shall have the right to terminate this Agreement, at Tarsa’s sole discretion, on written notice to Unigene
upon the filing by Unigene in any court or agency pursuant to any statute or regulation of the United States or any other jurisdiction a petition in bankruptcy or insolvency or for reorganization or similar arrangement for the benefit of creditors
or for the appointment of a receiver or trustee of Unigene or its assets, or if Unigene is served with an involuntary petition against it in any insolvency proceeding, upon the *** day after such service if such involuntary petition has not
previously been stayed or dismissed, or upon the making by Unigene of an assignment of substantially all of its assets for the benefit of its creditors. 
 (b) Material Breach. Tarsa may terminate this Agreement in the event of any material breach by Unigene of any terms and conditions of this Agreement, provided that such breach has not been
cured within *** days after written notice thereof is given by Tarsa to Unigene. 
 (c) Without Cause. Commencing on the
earlier of (a) the *** of the Effective Date and (b) acceptance by the FDA of an application for Regulatory Approval of the Licensed Calcitonin Product, Tarsa may terminate this Agreement at any time with or without cause on a Licensed
Product-by-Licensed Product basis on *** days prior written notice. 
 Section 9.4. Effect of Termination by Unigene for
Material Breach of Tarsa, by Tarsa Without Cause or for Insolvency. Upon any termination of this Agreement pursuant to Section 9.2(a), Section 9.2(b), Section 9.3(a) (without limitation of
Section 9.8) or Section 9.3(c), the rights and obligations of the Parties hereunder, and all licenses granted to Tarsa hereunder with respect to the terminated Licensed Product, shall immediately cease (except as otherwise
provided in this Section 9.4), and: 
 (a) All amounts due or payable to Unigene prior to the effective date of
termination, and all non-cancelable costs and expenses incurred by Unigene in connection with this Agreement, shall remain due and payable. 
 (b) Should Tarsa have any inventory of the terminated Licensed Product approved and allocated for commercial sale prior to termination, other than upon the occurrence of a material breach by Tarsa
pursuant to Section 9.2(b), Tarsa shall have the right to dispose of such inventory after termination of this Agreement with respect to such terminated Licensed Product (subject to the payment to Unigene of any royalties due hereunder
thereon), provided however that such terminated Licensed Product shall not be sold at a discount to a purchaser that is greater than the average discount provided to such purchaser for the Licensed Products in the Territory during the ***
period preceding such termination and, in addition, such sales shall not result in the applicable wholesaler inventory levels for such terminated Licensed Product exceeding *** of the average levels for the *** period preceding such termination. If
Unigene terminates this Agreement pursuant to Section 9.2(b), Tarsa and its Affiliates and Sublicensees shall immediately cease all sales of the terminated Licensed Products. 
 (c) In the event the termination is with respect to the Licensed Calcitonin Product, Tarsa shall be responsible for payment to Unigene in
respect of Calcitonin API that it has ordered or forecast in the amounts specified in Clause 21(e) of the CM Agreement. 
  

 - 43 - 

 (d) Except for a termination by Unigene pursuant to Section 9.2(b) arising as a
result of a breach by a Sublicensee of the terms, conditions and limitations set forth herein, upon any termination of this Agreement where Tarsa has designated a non-Affiliate as a Sublicensee as permitted hereunder, Unigene shall offer such
Sublicensee the right to enter into a license agreement directly with Unigene on substantially the same terms and conditions under which such rights and licenses were granted to such Sublicensee and pending the execution of this license agreement,
Unigene shall automatically grant each Sublicensee a temporary continuation, not to exceed *** days, of the rights under this Agreement originally sublicensed to the Sublicensee by Tarsa, provided that Unigene shall have no obligations under
this Section 9.4(d) such Sublicensee (i) is in material compliance with the Sublicense terms; (ii) agrees in writing with Unigene to be bound by the terms, conditions and limitations relating to the Licensed IP and Confidential
Information as set forth hereunder; and (iii) such agreement does not include obligations upon Unigene that exceed the obligations of Unigene under this Agreement. 
 (e) Each Party shall return (or purge its systems and files of, and suitably account for) all tangible Confidential Information supplied to, or otherwise obtained by, it from the other Party in connection
with the terminated Licensed Product, except that such Party shall be entitled to retain, through its legal counsel, one (1) copy of such Confidential Information to the extent required under any applicable law, rule or regulation. Each Party
shall certify in writing that it has fully complied with its obligations under this Section 9.4(e) within *** days after its receipt of a request by the other Party for such a certification. 
 (f) Tarsa shall assign and transfer, and shall cause its Sublicensees to assign and transfer, at Tarsa’s expense, to Unigene
(i) all regulatory filings, registrations, applications, Regulatory Approvals and information and data relating to the applicable terminated Licensed Products and (ii) any Assigned Contracts applicable to such terminated Licensed Product
requested by Unigene. 
 Section 9.5. Tarsa’s Remedies for Material Breach by Unigene. If Tarsa has the right
to terminate this Agreement with respect to a Licensed Product pursuant to Section 9.3(b) due to a material breach of Unigene that is not cured in accordance with Section 9.3(b), Tarsa may elect upon written notice to
Unigene, to either: (a) terminate this Agreement in its entirety with respect to such Licensed Product and *** or (b) maintain this Agreement in full force and effect (foregoing, for the avoidance of doubt, the right to terminate this
Agreement for such occurrence of such breach) and elect one of the following as its sole and exclusive remedy for such occurrence of such breach: (i) seek any remedies Tarsa may have at law or in equity with respect to such breach or
(ii) have the following provisions apply to the Licensed Product that is the subject of the applicable breach by Unigene: (A) all *** in respect of such Licensed Product payable by Tarsa under this Agreement following such election shall
be subject to a *** of ***, (B) Tarsa shall have *** in respect of such Licensed Product *** such election and (C) Tarsa shall not be licensed under any Unigene Sole Improvements or Collaboration Improvements in respect of such Licensed
Product conceived, discovered, developed or authored solely by or on behalf of Unigene (whether alone or with Third Parties) after the date of such election. For the avoidance of doubt, in the event Tarsa elects the remedy described in clause
(A) above, the *** applicable to such Licensed Product thereafter shall not be subject to further *** pursuant to this Section 9.5. 
  

 - 44 - 

 Section 9.6. Remedies. Except as otherwise expressly set forth in this
Agreement, the termination provisions of this ARTICLE IX are in addition to any other relief and remedies available to either Party at law or in equity. 
 Section 9.7. Surviving Provisions. Notwithstanding any provision herein to the contrary, the rights and obligations of the Parties set forth in Section 2.9 (Non-Solicitation),
Section 3.1 (Unigene right of reference, except where this Agreement has been terminated pursuant to Section 9.3(b)), Section 4.5 (Sales Reports and Royalty Payment) (with respect to the last calendar quarter of
the Term), Section 4.7 (Sales Record Audit), Section 8.3 (No Warranties), Section 8.4 (Indemnification) and Section 8.5 (Limitation of Liability) and ARTICLE V (Confidential Information), ARTICLE VI
(Intellectual Property), ARTICLE IX (Term and Termination) and ARTICLE X (Miscellaneous) (and any definitions referred to therein), as well as any rights or obligations otherwise accrued hereunder (including any accrued payment obligations), shall
survive the termination of this Agreement for any reason. 
 Section 9.8. Bankruptcy Rights. All rights and licenses
granted under or pursuant to this Agreement by a Party are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” as defined under
Section 101 of the U.S. Bankruptcy Code. The Parties agree that a Party, as a licensee of intellectual property under this Agreement, shall retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code. The
Parties further agree that, in the event of a rejection of this Agreement by a Party in any bankruptcy proceeding by or against such Party under the U.S. Bankruptcy Code, (a) the other Party shall be entitled to a complete duplicate of (or
complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, which, if not already in such other Party’s possession, shall be promptly delivered to it upon written request therefor, and
(b) such Party shall not interfere with the other Party’s rights to intellectual property and all embodiments of intellectual property, and shall assist and not interfere with the other Party in obtaining intellectual property and all
embodiments of intellectual property from another entity. The term “embodiments” of intellectual property includes all tangible, intangible, electronic or other embodiments of rights and licenses hereunder, including all compounds and
products embodying intellectual property, Licensed Products, regulatory filings and related rights, and Licensed IP and Improvements. 
 ARTICLE X 
 MISCELLANEOUS 
 Section 10.1. Notification. All notices, requests and other communications hereunder shall be in writing, shall be addressed to the receiving Party’s address set forth below or to such
other address as a Party may designate by notice hereunder, and shall be either (a) delivered by hand, (b) made by facsimile transmission (to be followed with written confirmation by the delivering Party), (c) sent by private courier
service providing evidence of receipt, or (d) sent by registered or certified mail, return receipt requested, postage prepaid. The addresses and other contact information for the Parties are as follows: 
  

			
	If to Unigene:	  	 Unigene Laboratories, Inc.
 81 Fulton Street, Boonton
 NJ 07005 USA
 Attn: Ronald S. Levy
 Fax: 973-335-0972

  

 - 45 - 

			
	With a copy to:	  	 Dechert LLP
 Suite
500
 902 Carnegie Center
 Princeton, NJ
08540-6531
 Attn: James J. Marino
 Fax:
609-955-3259

		
	If to Tarsa:	  	 Tarsa Therapeutics, Inc.
 c/o MVM Life Science Partners LLP
 Old City Hall
 45 School Street
 Boston MA 02108
 Attn: President
 Fax: 617-383-2106

		
	With a copy to:	  	 Ropes & Gray LLP
 One
International Place
 Boston, MA 02110
 Attn: Marc A. Rubenstein
 Fax: 617-951-7050

 All notices, requests and other communications hereunder shall be deemed to have been given either (i) if by hand,
at the time of the delivery thereof to the receiving Party at the address of such Party set forth above, (ii) if made by facsimile transmission, at the time that receipt thereof has been acknowledged by the recipient, (iii) if sent by
private courier, on the day such notice is delivered to the recipient, or (iv) if sent by registered or certified mail, on the fifth (5th) business day following the day such mailing is made. 
 Section 10.2. Language. This Agreement has been prepared in the English language and the English language shall control its
interpretation. 
 Section 10.3. Governing Law; Jurisdiction. This Agreement shall be deemed to have been made in
the State of New York, U.S.A., and its form, execution, validity, construction and effect shall be determined in accordance with, and any dispute arising from the performance or breach hereof shall be governed by and construed in accordance with,
the laws of the State of New York, excluding its body of law controlling conflicts of law. Each of the Parties irrevocably submits to the exclusive jurisdiction of the federal and state courts situated in the State of New York for purposes of any
suit, action or proceeding arising out of this Agreement or any transaction contemplated hereby and agrees not to commence any action, suit or proceeding related hereto except in such courts. Neither Party shall challenge or contest the subject
matter or personal jurisdiction of any such court or its venue or assert the defense of forum nonconveniens. 
  

 - 46 - 

 Section 10.4. Entire Agreement. This Agreement, together with all of its
Schedules, constitutes the entire agreement between the Parties with respect to the subject matter hereof and supersedes all prior representations, understandings and agreements between the Parties with respect to the subject matter hereof. No
modification to this Agreement shall be effective unless in writing with specific reference to this Agreement and signed by the Parties. 
 Section 10.5. Waiver. The terms or conditions of this Agreement may be waived only by a written instrument executed by the Party waiving compliance. The failure of either Party at any time or
times to require performance of any provision hereof shall in no manner affect its rights at a later time to enforce the same. No waiver by either Party of any condition or term shall be deemed as a continuing waiver of such condition or term or of
another condition or term. 
 Section 10.6. Headings. Section and subsection headings are inserted for convenience
of reference only and do not form part of this Agreement. 
 Section 10.7. Assignment. This Agreement shall not be
assignable by either Party to any Affiliate or Third Party without the prior written consent of the other Party hereto, except (a) pursuant to the Collateral Assignment, (b) in connection with any Foreclosure Action or Third Party Sale
(each, as defined in the ROFO/ROFR Agreement) and (c) to an entity that acquires all or substantially all of the capital stock, business or assets of the Party to which this Agreement pertains (whether by merger, reorganization, acquisition,
sale or otherwise), provided that in each case the assigning Party provides written notice to the other Party of such assignment and the assignee agrees in writing to be bound by the terms and conditions of this Agreement. Any permitted assignee
shall assume all obligations of its assignor under this Agreement. Any purported assignment in violation of this Section 10.7 shall be null and void, ab initio. 
 Section 10.8. Force Majeure. Except for obligations of payment arising hereunder, neither Party shall be liable to the other for
failure or delay in the performance of any of its obligations under this Agreement for the time and to the extent such failure or delay is caused by earthquake, riot, civil commotion, terrorism, war, hostilities between nations, governmental law,
order or regulation, embargo, action by the government or any agency thereof, act of God, storm, fire, accident, labor dispute or strike, sabotage, explosion or other similar or different contingencies, in each case, beyond the reasonable control of
the respective Party. The Party affected by force majeure shall provide the other Party with full particulars thereof as soon as it becomes aware of the same (including its best estimate of the likely extent and duration of the interference with its
activities), and shall use its commercially reasonable efforts to overcome the difficulties created thereby and to resume performance of its obligations as soon as practicable. If the performance of any obligation under this Agreement is delayed
owing to a force majeure for any continuous period of more than three (3) months, the Parties hereto shall consult with respect to an equitable solution including the possible termination of this Agreement. 
 Section 10.9. Construction. The Parties hereto acknowledge and agree that: (a) each Party and its counsel reviewed and
negotiated the terms and provisions of this Agreement and have contributed to its revision; (b) the rule of construction to the effect that any ambiguities are resolved against the drafting Party shall not be employed in the interpretation of
this Agreement; and (c) the terms and provisions of this Agreement shall be construed fairly as to all Parties hereto and not in favor of or against any Party, regardless of which Party was generally responsible for the preparation of this
Agreement. Neither Party shall challenge the validity or enforceability of the terms, conditions, obligations and covenants hereunder. 
  

 - 47 - 

 Section 10.10. Severability. If any provision(s) of this Agreement are or become
invalid, are ruled illegal by any court of competent jurisdiction or are deemed unenforceable under then current applicable law from time to time in effect during the Term hereof, it is the intention of the Parties that the remainder of this
Agreement shall not be affected thereby provided that a Party’s rights under this Agreement are not materially affected. The Parties hereto covenant and agree to renegotiate any such term, covenant or application thereof in good faith in
order to provide a reasonably acceptable alternative to the term, covenant or condition of this Agreement or the application thereof that is invalid, illegal or unenforceable, it being the intent of the Parties that the basic purposes of this
Agreement are to be effectuated. 
 Section 10.11. Status. Nothing in this Agreement is intended or shall be deemed
to constitute a partner, agency, employer-employee, or joint venture relationship between the Parties. 
 Section 10.12.
Further Assurances. Each Party agrees to execute, acknowledge and deliver such further instructions, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.

 Section 10.13. Counterparts. This Agreement may be executed simultaneously in one or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
  

 - 48 - 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized
representative. 
  

									
	UNIGENE LABORATORIES, INC.	 		 	TARSA THERAPEUTICS, INC.
					
	By:	 	 /s/ Warren P. Levy
	 		 	By:	 	 /s/ D. M. Brand

					
	Name:	 	 Warren P. Levy
	 		 	Name:	 	 D. M. Brand

					
	Title:	 	 President & CEO
	 		 	Title:	 	 President/CEO

 Schedule 1 
 Part I 
 Assigned Contracts 
 *** 

 Part II 
 Retained Agreements 
 *** 
  

 ii 

 Schedule 2 
 Licensed Patent Rights 
 Licensed Calcitonin
Formulation Patent Rights 
 *** 
 Licensed Calcitonin Manufacturing Patent Rights and Licensed *** Patent Rights 
 *** 
  

 iii 

 Schedule 3 
 *** Specifications 
 *** 
  

 iv 

 Schedule 4 
 Development Timeline 
 *** 
  

 v 

 Schedule 5 
 Form of Calcitonin IND Assignment 
 Scott E. Monroe, M.D. 

Director, Division of Reproductive and Urology Products 
 Center for Drug Evaluation and Research 
 Food and Drug Administration 
 5901-B Ammendale Road 
 Beltsville, MD 20705-1266 
  

			
	Re:	  	 IND *** – Recombinant Salmon Calcitonin Tablets

		  	 Notice of IND Transfer

		  	 Serial No. ***

 Dear Dr. Monroe, 
 Please be advised that Tarsa Therapeutics, Inc. located at Old City Hall, 45 School Street, Boston, MA 02108
hereby acknowledges transfer of ownership of IND *** for *** for recombinant salmon calcitonin tablets from Unigene Laboratories, Inc. to Tarsa Therapeutics, Inc. 
 As described in the attached letter from Unigene, Tarsa Therapeutics, Inc. has received a complete copy of the IND from Unigene Laboratories, Inc. and accepts responsibility for all agreements,
commitments and conditions made by Unigene Laboratories, Inc. in the IND. 
 The change in ownership is effective [Date], 2009.
Accordingly, as of the effective date, please direct all correspondence and communications regarding IND *** to: 
 Dave Brand

 Tarsa Therapeutics, Inc. 
 c/o MVM
Life Science Partners 
 Old City Hall 
 45 School Street 
 Boston, MA 02108 
 267-386-4848 
 Should you have any questions or concerns regarding this matter, please do not hesitate to contact me at 973-265-1100
or by email at rlevy@unigene.com. 
 Sincerely, 
 Ronald S. Levy, Ph.D. 
 Executive Vice President 
 Attachments: Copy of IND transfer letter from Unigene Laboratories, Inc. 
  

 vi 

 Scott E. Monroe, M.D. 
 Director, Division of Reproductive and Urology Products 
 Center for Drug Evaluation and Research

 Food and Drug Administration 
 5901-B
Ammendale Road 
 Beltsville, MD 20705-1266 
  

			
	Re:	  	 IND *** – Recombinant Salmon Calcitonin Tablets

		  	 Notice of IND Transfer

		  	 Serial No. ***

 Dear Dr. Monroe: 
 Reference is made to IND *** for *** for recombinant salmon calcitonin tablets submitted to the
Division of Metabolic and Endocrine Products on *** by *** and subsequently transferred to Unigene Laboratories, Inc. on ***. 
 Please be advised that Unigene Laboratories, Inc., located at 81 Fulton Street, Boonton, NJ 07005 hereby transfers ownership, including all rights and responsibilities for this IND, to Tarsa Therapeutics, Inc., located at Old City Hall, 45
School Street, Boston, MA 02108. 
 As described in the attached letter, Tarsa Therapeutics, Inc. has received a complete copy of the IND from
Unigene Laboratories, Inc. and accepts responsibility for any agreements, commitments and conditions made by Unigene Laboratories, Inc. in the IND. 
 The change in ownership is effective [Date], 2009. Accordingly, as of the effective date, please direct all correspondence and communications regarding IND *** to: 
 Dave Brand 
 Tarsa Therapeutics, Inc. 
 c/o MVM Life Science Partners 
 Old City Hall 
 45 School Street 
 Boston, MA 02108 
 267-386-4848 
 Should you have any questions or
concerns regarding this matter, please do not hesitate to contact me at 973-265-1100 or by email at rlevy@unigene.com. 
 Sincerely, 

Ronald S. Levy, Ph.D. 
 Executive Vice President 
  

 vii 

 Schedule 6 
 Assigned Contract Consents 
 *** 
  

 viii 

 Schedule 7 
 List of Unigene’s Knowledge 
 *** 
  

 ix

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}]]